<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Intensive versus conventional glycaemic control for treating diabetic foot ulcers - Fernando, ME - 2016 | Cochrane Library</title> <meta content="Intensive versus conventional glycaemic control for treating diabetic foot ulcers - Fernando, ME - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010764.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Intensive versus conventional glycaemic control for treating diabetic foot ulcers - Fernando, ME - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010764.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010764.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Intensive versus conventional glycaemic control for treating diabetic foot ulcers" name="citation_title"/> <meta content="Malindu E Fernando" name="citation_author"/> <meta content="malindu.fernando@my.jcu.edu.au" name="citation_author_email"/> <meta content="Ridmee M Seneviratne" name="citation_author"/> <meta content="College of Medicine and Dentistry, James Cook University" name="citation_author_institution"/> <meta content="Yong Mong Tan" name="citation_author"/> <meta content="The Townsville Hospital" name="citation_author_institution"/> <meta content="Peter A Lazzarini" name="citation_author"/> <meta content="Kunwarjit S Sangla" name="citation_author"/> <meta content="The Townsville Hospital" name="citation_author_institution"/> <meta content="Margaret Cunningham" name="citation_author"/> <meta content="University of Stirling" name="citation_author_institution"/> <meta content="Petra G Buttner" name="citation_author"/> <meta content="Tropical Health Solutions Pty Ltd" name="citation_author_institution"/> <meta content="Jonathan Golledge" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD010764.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/01/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010764.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010764.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010764.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Diabetes Mellitus, Type 1 [*complications]; Diabetes Mellitus, Type 2 [*complications]; Diabetic Foot [etiology, *therapy]; Hyperglycemia [complications, *therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010764.pub2&amp;doi=10.1002/14651858.CD010764.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="loVWuZlx";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010764\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010764\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","pl","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010764.pub2",title:"Intensive versus conventional glycaemic control for treating diabetic foot ulcers",firstPublishedDate:"Jan 13, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Wounds Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010764.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010764.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010764.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010764.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010764.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010764.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010764.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010764.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010764.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010764.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6042 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010764.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/full#CD010764-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/full#CD010764-sec-0063"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/full#CD010764-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/full#CD010764-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/full#CD010764-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/full#CD010764-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/full#CD010764-sec-0062"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/appendices#CD010764-sec-0067"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Intensive versus conventional glycaemic control for treating diabetic foot ulcers</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/information#CD010764-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Malindu E Fernando</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/information#CD010764-cr-0003">Ridmee M Seneviratne</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/information#CD010764-cr-0004">Yong Mong Tan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/information#CD010764-cr-0005">Peter A Lazzarini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/information#CD010764-cr-0006">Kunwarjit S Sangla</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/information#CD010764-cr-0007">Margaret Cunningham</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/information#CD010764-cr-0008">Petra G Buttner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010764.pub2/information#CD010764-cr-0009">Jonathan Golledge</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/information/en#CD010764-sec-0072">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 January 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010764.pub2">https://doi.org/10.1002/14651858.CD010764.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010764-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010764-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010764-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010764-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010764-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010764-abs-0001" lang="en"> <section id="CD010764-sec-0001"> <h3 class="title" id="CD010764-sec-0001">Background</h3> <p>The estimated likelihood of lower limb amputation is 10 to 30 times higher amongst people with diabetes compared to those without diabetes. Of all non‐traumatic amputations in people with diabetes, 85% are preceded by a foot ulcer. Foot ulceration associated with diabetes (diabetic foot ulcers) is caused by the interplay of several factors, most notably diabetic peripheral neuropathy (DPN), peripheral arterial disease (PAD) and changes in foot structure. These factors have been linked to chronic hyperglycaemia (high levels of glucose in the blood) and the altered metabolic state of diabetes. Control of hyperglycaemia may be important in the healing of ulcers. </p> </section> <section id="CD010764-sec-0002"> <h3 class="title" id="CD010764-sec-0002">Objectives</h3> <p>To assess the effects of intensive glycaemic control compared to conventional control on the outcome of foot ulcers in people with type 1 and type 2 diabetes. </p> </section> <section id="CD010764-sec-0003"> <h3 class="title" id="CD010764-sec-0003">Search methods</h3> <p>In December 2015 we searched: The Cochrane Wounds Specialised Register; The Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i>); Ovid MEDLINE; Ovid MEDLINE (In‐Process &amp; Other Non‐Indexed Citations); Ovid EMBASE; EBSCO CINAHL; Elsevier SCOPUS; ISI Web of Knowledge Web of Science; BioMed Central and LILACS. We also searched clinical trial databases, pharmaceutical trial databases and current international and national clinical guidelines on diabetes foot management for relevant published, non‐published, ongoing and terminated clinical trials. There were no restrictions based on language or date of publication or study setting. </p> </section> <section id="CD010764-sec-0004"> <h3 class="title" id="CD010764-sec-0004">Selection criteria</h3> <p>Published, unpublished and ongoing randomised controlled trials (RCTs) were considered for inclusion where they investigated the effects of intensive glycaemic control on the outcome of active foot ulcers in people with diabetes. Non randomised and quasi‐randomised trials were excluded. In order to be included the trial had to have: 1) attempted to maintain or control blood glucose levels and measured changes in markers of glycaemic control (HbA1c or fasting, random, mean, home capillary or urine glucose), and 2) documented the effect of these interventions on active foot ulcer outcomes. Glycaemic interventions included subcutaneous insulin administration, continuous insulin infusion, oral anti‐diabetes agents, lifestyle interventions or a combination of these interventions. The definition of the interventional (intensive) group was that it should have a lower glycaemic target than the comparison (conventional) group. </p> </section> <section id="CD010764-sec-0005"> <h3 class="title" id="CD010764-sec-0005">Data collection and analysis</h3> <p>All review authors independently evaluated the papers identified by the search strategy against the inclusion criteria. Two review authors then independently reviewed all potential full‐text articles and trials registry results for inclusion. </p> </section> <section id="CD010764-sec-0006"> <h3 class="title" id="CD010764-sec-0006">Main results</h3> <p>We only identified one trial that met the inclusion criteria but this trial did not have any results so we could not perform the planned subgroup and sensitivity analyses in the absence of data. Two ongoing trials were identified which may provide data for analyses in a later version of this review. The completion date of these trials is currently unknown. </p> </section> <section id="CD010764-sec-0007"> <h3 class="title" id="CD010764-sec-0007">Authors' conclusions</h3> <p>The current review failed to find any completed randomised clinical trials with results. Therefore we are unable to conclude whether intensive glycaemic control when compared to conventional glycaemic control has a positive or detrimental effect on the treatment of foot ulcers in people with diabetes. Previous evidence has however highlighted a reduction in risk of limb amputation (from various causes) in people with type 2 diabetes with intensive glycaemic control. Whether this applies to people with foot ulcers in particular is unknown. The exact role that intensive glycaemic control has in treating foot ulcers in multidisciplinary care (alongside other interventions targeted at treating foot ulcers) requires further investigation. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010764-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010764-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010764-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010764-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010764-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010764-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010764-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD010764-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010764-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010764-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010764-abs-0003" lang="en"> <h3>Controlling blood glucose in treating diabetic foot ulcers (sores)</h3> <p><b>Background:</b> People with diabetes can develop foot ulcers (sores) for a number of reasons. This includes nerve damage and reduced blood flow to the feet and legs. Having high blood glucose may affect the ability of foot ulcers to heal and therefore intensively controlling blood glucose may be beneficial. </p> <p><b>Review question:</b> This Cochrane review aimed to answer the question; how does controlling blood glucose more intensively compared to conventional blood glucose control influence foot ulcer healing in people with diabetes? </p> <p><b>What we found:</b> We did not find any trials which have been completed on this topic with available results. The only trial which met our criteria for inclusion had been terminated due to encountering difficulties with recruiting participants. Therefore we cannot be sure whether controlling blood glucose intensively when people have diabetic foot ulcers is beneficial or harmful. The lack of evidence however should not deter efforts to achieve optimal glycaemic control in people with diabetic foot ulcers to encourage healing as is current practice. We believe there are currently two trials underway which may provide some evidence on this topic once completed. </p> <p>This Plain Language Summary is up to date as of 7 December 2015.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010764-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010764-sec-0063">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010764-sec-0097">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010764-sec-0063"></div> <h3 class="title" id="CD010764-sec-0064">Implications for practice</h3> <section id="CD010764-sec-0064"> <p>The current review failed to find any randomised clinical trials with results. Therefore we are unable to conclude whether intensive glycaemic control when compared to conventional glycaemic control has a positive or detrimental effect on the treatment of foot ulcers.The exact role and place that intensive glycaemic control may have on treating foot ulcers remains to be resolved. </p> </section> <h3 class="title" id="CD010764-sec-0065">Implications for research</h3> <section id="CD010764-sec-0065"> <p>Independent, well‐designed, large RCTs may be required to investigate the benefits and adverse effects of intensive versus conventional glycaemic control on diabetic foot ulcer outcomes.Those who are considering research in this area should consider the challenges of conducting a trial on this topic which have been outlined in the discussion. Ideally future RCTs investigating this topic should be specifically designed and tailored to answer the question of superiority of intensive over conventional glycaemic control. In particular future research should aim to: </p> <p> <ul id="CD010764-list-0029"> <li> <p>consider ulcer‐specific outcome measures (i.e. healing) in addition to amputation;</p> </li> <li> <p>find ways to control, adjust or match for ulcer characteristics, participant characteristics and the various interventions required for optimal ulcer healing using appropriate randomisation, adjustment or stratification; </p> </li> <li> <p>assess the role of intensive versus conventional glycaemic control in predisposing to diabetic foot ulcer infection as well as foot ulcer healing; </p> </li> <li> <p>have a sample size that is large enough to test a statistically significant effect and be large enough to allow for subgroup analyses. </p> </li> </ul> </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010764-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010764-sec-0022">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010764-sec-0082">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD010764-sec-0022"></div> <section id="CD010764-sec-0023"> <h3 class="title" id="CD010764-sec-0023">Description of the condition</h3> <p>In 2011, 366 million people worldwide (8.3% of adults) were estimated to have diabetes mellitus (<a href="./references#CD010764-bbs2-0081" title="International Diabetes Federation. IDF diabetes atlas update 2012. The global burden. http://www.idf.org/diabetesatlas/5e/the‐global‐burden (accessed 10 December 2012). ">IDF 2012</a>). It is expected that this figure will reach 552 million (10% of adults) by 2030 (<a href="./references#CD010764-bbs2-0081" title="International Diabetes Federation. IDF diabetes atlas update 2012. The global burden. http://www.idf.org/diabetesatlas/5e/the‐global‐burden (accessed 10 December 2012). ">IDF 2012</a>). Diabetes mellitus is a metabolic disorder characterised by dysregulation of blood glucose levels. Type 1 diabetes (previously known as insulin‐dependent, juvenile or childhood‐onset) is characterised by deficient insulin production and requires daily administration of insulin (<a href="./references#CD010764-bbs2-0081" title="International Diabetes Federation. IDF diabetes atlas update 2012. The global burden. http://www.idf.org/diabetesatlas/5e/the‐global‐burden (accessed 10 December 2012). ">IDF 2012</a>). The cause of type 1 diabetes is not known and it is currently not preventable (<a href="./references#CD010764-bbs2-0081" title="International Diabetes Federation. IDF diabetes atlas update 2012. The global burden. http://www.idf.org/diabetesatlas/5e/the‐global‐burden (accessed 10 December 2012). ">IDF 2012</a>). Type 2 diabetes (formerly known as non‐insulin‐dependent or adult‐onset) results from the body’s ineffective use of insulin. Ninety per cent of people with diabetes, worldwide, have type 2 diabetes (<a href="./references#CD010764-bbs2-0081" title="International Diabetes Federation. IDF diabetes atlas update 2012. The global burden. http://www.idf.org/diabetesatlas/5e/the‐global‐burden (accessed 10 December 2012). ">IDF 2012</a>). One of the major complications of diabetes is diabetic foot ulceration (<a href="./references#CD010764-bbs2-0055" title="BoultonAJM . The diabetic foot: from art to science: the 18th Camillo Golgi lecture. Diabetologia2004;47(8):1343‐53. ">Boulton 2004</a>). A diabetic foot ulcer (an ulcer which occurs due to diabetes) has been defined as either a full‐thickness wound below the ankle in people with diabetes, irrespective of duration (<a href="./references#CD010764-bbs2-0052" title="ApelqvistJ , LarssonJ . What is the most effective way to reduce incidence of amputation in the diabetic foot?. Diabetes/Metabolism Research and Reviews1999;16(Suppl 1):75‐83. ">Apelqvist 1999</a>), or a lesion of the foot penetrating through the dermis (<a href="./references#CD010764-bbs2-0101" title="SchaperNC . Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes/Metabolism Research and Reviews2004;20(Suppl 1):S90–5. ">Schaper 2004</a>). The prevalence of foot ulceration in people diagnosed with diabetes is 4% to 10%; the annual population incidence is 1% to 4%, and the lifetime incidence is as high as 25% (<a href="./references#CD010764-bbs2-0107" title="SinghN , ArmstrongDG , LipskyBA . Preventing foot ulcers in patients with diabetes. JAMA2005;293(2):217‐28. ">Singh 2005</a>). In a recent multi‐centre study, poor glycaemic (blood glucose) control was evident in nearly half of the participants who had foot ulcers, with 49% having an HbA1c (glycaemic measure) level above 8.4% (<a href="./references#CD010764-bbs2-0102" title="SchaperNC . Lessons from Eurodiale. Diabetes/Metabolism Research and Reviews2012;28(Suppl 1):21‐6. ">Schaper 2012</a>). </p> <p>Foot ulceration is caused by the interplay of several factors, most notably diabetic peripheral neuropathy (DPN, i.e. loss of sensation to the foot), peripheral arterial disease (PAD, i.e. lack of blood‐flow) and changes in foot structure (<a href="./references#CD010764-bbs2-0060" title="ClaytonW , ElasyTA . A review of the pathophysiology, classification, and treatment of foot ulcers in diabetic patients. Journal of Clinical Diabetes2009;27(2):52‐8. ">Clayton 2009</a>; <a href="./references#CD010764-bbs2-0105" title="ShenoyAM . Guidelines in practice: treatment of painful diabetic neuropathy. Continuum Lifelong Learning in Neurology2012;18(1):192‐8. ">Shenoy 2012</a>). These factors have been linked to chronic hyperglycaemia and the altered metabolic state associated with diabetes (<a href="./references#CD010764-bbs2-0082" title="IkemR , IkemI , AdebayoO , SoyoyeD . An assessment of peripheral vascular disease in patients with diabetic foot ulcer. The Foot2010;20(4):114‐7. ">Ikem 2010</a>; <a href="./references#CD010764-bbs2-0096" title="OgberaOA , OsaE , EdoA , ChukwumE . Common clinical features of diabetic foot ulcers: perspectives from a developing nation. International Journal of Lower Extremity Wounds2008;7(2):93‐8. ">Ogbera 2008</a>; <a href="./references#CD010764-bbs2-0111" title="TesfayeS , SelvarajahD . Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes/Metabolism Research and Reviews2012;1(1):8‐14. ">Tesfaye 2012</a>).The prevalence of DPN ranges from 16% to 66% in people with diabetes (<a href="./references#CD010764-bbs2-0061" title="CookJJ , SimonsonDC . Epidemiology and health care cost of diabetic foot problems. In: VevesA editor(s). The Diabetic Foot: Medical and Surgical Management. Boston: Contemporary Diabetes, 2012:17‐32. ">Cook 2012</a>). The prevalence rates of PAD are as high as 50% in people with diabetic foot ulcers (<a href="./references#CD010764-bbs2-0079" title="HinchliffeRJ ,  AndrosG ,  ApelqvistJ ,  BakkerK ,  FriederichsS ,  LammerJ , et al. A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes/Metabolism Research and Reviews2012;28(Suppl 1):179‐217. ">Hinchliffe 2012</a>). What is most notable is that within one year of an ulcer healing, up to 60% of patients will develop another foot ulcer (<a href="./references#CD010764-bbs2-0113" title="WuSC , DriverVR , WrobelJS , ArmstrongDG . Foot ulcers in the diabetic patient, prevention and treatment. Journal of Vascular Health Risk Management2007;3(1):65‐76. ">Wu 2007</a>), and often the end point is lower limb amputation. </p> <p>It is currently estimated that there is an amputation every 30 seconds, somewhere in the world that is due to diabetes (<a href="./references#CD010764-bbs2-0070" title="GameF . Choosing life or limb. Improving survival in the multi‐complex diabetic foot patient. Diabetes/Metabolism Research and Reviews2012;28(Suppl 1):97‐100. ">Game 2012</a>). The estimated likelihood of amputation is 10 to 30 times higher amongst people with diabetes compared to those without diabetes and 85% of all amputations in people with diabetes are preceded by a foot ulcer (<a href="./references#CD010764-bbs2-0055" title="BoultonAJM . The diabetic foot: from art to science: the 18th Camillo Golgi lecture. Diabetologia2004;47(8):1343‐53. ">Boulton 2004</a>; <a href="./references#CD010764-bbs2-0107" title="SinghN , ArmstrongDG , LipskyBA . Preventing foot ulcers in patients with diabetes. JAMA2005;293(2):217‐28. ">Singh 2005</a>). The five‐year mortality rate after the onset of a foot ulcer ranges from 43% to 55%, and is up to 74% for patients with lower limb amputation (<a href="./references#CD010764-bbs2-0100" title="RobbinsJM , StraussG , AronD , LongJ , KubaJ , KaplanY . Mortality rates and diabetic foot ulcers: is it time to communicate mortality risk to patients with diabetic foot ulceration?. Journal of the American Podiatric Medical Association2008;98:489‐93. ">Robbins 2008</a>). </p> </section> <section id="CD010764-sec-0024"> <h3 class="title" id="CD010764-sec-0024">Description of the intervention</h3> <p>Chronic hyperglycaemia appears to be one of the most important factors in the development and healing of diabetic foot ulcers (<a href="./references#CD010764-bbs2-0059" title="ChristmanAL , SelvinE , MargolisDJ , LazarusGS , GarzaLA . Hemoglobin A1c predicts healing rate in diabetic wounds. Journal of Investigative Dermatology2011;131(10):2121‐7. ">Christman 2011</a>; <a href="./references#CD010764-bbs2-0069" title="FalangaV . Wound healing and its impairment in the diabetic foot. The Lancet2005;366(9498):1736–43. ">Falanga 2005</a>). Current guidelines recommend that treatment of diabetic foot ulcers should involve a multidisciplinary team, as well as utilising several interventions (<a href="#CD010764-tbl-0001">Table 1</a>). This review was performed to clarify the effect of intensive glycaemic control on the healing of foot ulcers in people with diabetes. </p> <div class="table" id="CD010764-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Diabetic foot management guidelines and levels of evidence</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Guideline and management recommendations </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Level of evidence </b> </p> <p><b>(According to Oxford Centre for Evidence‐based Medicine ‐ Levels of Evidence (March 2009))</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Glycaemic target</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>National Health and Medical Research Council (NHMRC):  Prevention, identification and management of foot complications in diabetes mellitus 2011</b> </p> <p> <ul id="CD010764-list-0001"> <li> <p>Local sharp debridement</p> </li> <li> <p>Topical hydrogel dressings</p> </li> <li> <p>Pressure reduction</p> </li> <li> <p>Offloading</p> </li> <li> <p>Removable offloading</p> </li> <li> <p>Multidisciplinary care management</p> </li> <li> <p>Negative pressure therapy</p> </li> <li> <p>Hyperbaric oxygen</p> </li> <li> <p>Larval therapy</p> </li> <li> <p>Cultured skin equivalents</p> </li> <li> <p>Skin grafting</p> </li> </ul> </p> <p>Note: as per NHMRC levels of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Expert opinion</p> <p>Grade B</p> <p>Grade B</p> <p>Grade B</p> <p>Expert opinion</p> <p>Grade C</p> <p>Grade B</p> <p>Grade B</p> <p>Grade C</p> <p>Grade B</p> <p>Grade D</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>National Clearinghouse Guidelines  2011</b> </p> <p> <ul id="CD010764-list-0002"> <li> <p>Debridement with multidisciplinary team</p> </li> <li> <p>Off‐loading of foot ulcers</p> </li> <li> <p>Pressure relieving support surfaces</p> </li> <li> <p>Negative pressure wound therapy</p> </li> <li> <p>Avoid the use of:</p> <ul id="CD010764-list-0003"> <li> <p>dermal or skin substitutes</p> </li> <li> <p>electrical stimulation therapy</p> </li> <li> <p>autologous platelet‐rich plasma gel</p> </li> <li> <p>regenerative wound matrices and dalteparin</p> </li> <li> <p>growth factors</p> </li> <li> <p>hyperbaric oxygen therapy</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA1c &lt; 7%</p> <p>Level B</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>National Clearinghouse guidelines 2012</b> </p> <p><b>(treatment of neuropathic wounds)</b> </p> <p> <ul id="CD010764-list-0004"> <li> <p>Assessment by a wound expert</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>  </p> <p> </p> <p>Grade C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>National Health Service (NHS): Type 2 diabetes: prevention and management of foot problems 2004</b> </p> <p> <ul id="CD010764-list-0005"> <li> <p>Urgent attention within 24 hours</p> </li> <li> <p>Multidisciplinary treatment</p> </li> <li> <p>Multidisciplinary team comprising a podiatrist, orthotists, specialised nurse, diabetologist; with unhindered access to suites for managing major wounds, antibiotic administration, urgent inpatient facilities, community nursing, microbiology and diabetic services </p> </li> <li> <p>Prompt Revascularisation</p> </li> <li> <p>Intensive systemic antibiotic therapy</p> </li> <li> <p>Appropriate wound dressing</p> </li> <li> <p>Close monitoring and regular wound dressing changes</p> </li> <li> <p>Debridement of dead tissue</p> </li> <li> <p>Total contact casting</p> </li> <li> <p>Hyperbaric oxygen, cultured human dermis, topical ketanserin or growth factors</p> </li> <li> <p>Foot care reminders</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Grade D</p> <p>Grade D</p> <p>Grade D</p> <p>Grade D</p> <p>Grade C</p> <p>Grade D</p> <p>Grade D</p> <p>Grade B</p> <p>Grade B</p> <p>Grade D</p> <p>Grade B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Not reported</p> <p> </p> <p> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>National Health Service (NHS): 2011 National Institute for Health and Care Excellence (NICE) clinical guideline. Developed by the Centre for Clinical Practice at NICE: Diabetic foot problems: inpatient management of diabetic foot problems</b> </p> <p> <ul id="CD010764-list-0006"> <li> <p>Debridement</p> </li> <li> <p>Wound dressings</p> </li> <li> <p>Offloading</p> </li> <li> <p>Antibiotics for infection</p> </li> <li> <p>Timing for surgical management.          </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p> </p> <p> </p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p> </p> <p> </p> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2012 International Working Group on Diabetic Foot (IWGDF): Global guideline for type 2 diabetes</b> </p> <p> <ul id="CD010764-list-0007"> <li> <p>Local wound care</p> </li> <li> <p>Relief of pressure</p> </li> <li> <p>Treatment of infection</p> </li> <li> <p>Metabolic control</p> </li> <li> <p>Restoration of skin perfusion</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Not reported</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>&lt; 8 mmol/l</p> <p> </p> <p> </p> <p> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Australian diabetic foot Network: Management of diabetes related foot ulceration ‐ a clinical update</b> </p> <p> <ul id="CD010764-list-0008"> <li> <p>Debridement</p> </li> <li> <p>Dressing selection</p> </li> <li> <p>Pressure offloading</p> </li> <li> <p>Management of infection</p> </li> <li> <p>Glycaemic control</p> </li> <li> <p>Multidisciplinary care</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p> </p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p> </p> <p> Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>American College of Foot and Ankle surgeons 2006 (revision): Diabetic foot disorders – a clinical practice guideline</b> </p> <p> <ul id="CD010764-list-0009"> <li> <p>Debridement</p> </li> <li> <p>Pressure offloading</p> </li> <li> <p>Treatment of infection</p> </li> <li> <p>Optimise metabolic perturbations</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scottish Intercollegiate Guidelines Network (SIGN) Guidelines 2010</b> </p> <p> <ul id="CD010764-list-0010"> <li> <p>Referral to a multidisciplinary care team</p> </li> <li> <p>Total contact casts for unilateral ulcers</p> </li> <li> <p>Irremovable walkers</p> </li> <li> <p>Negative pressure wound therapy</p> </li> <li> <p>Arterial reconstruction for those who require it </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Grade C</p> <p>Grade B</p> <p>Grade B</p> <p>Grade B</p> <p>Grade B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>American Diabetes Association Standards of Medical Care in Diabetes 2012</b> </p> <p> <ul id="CD010764-list-0011"> <li> <p>Multidisciplinary approach</p> </li> <li> <p>Foot ulcers and wound care may require care by a podiatrist, orthopedic or vascular surgeon, or rehabilitation specialist experienced in the management of individuals with diabetes </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Grade B</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>As per position Statement for optimal Control </p> </td> </tr> </tbody> </table> </div> <p>The management of diabetes includes glycaemic control (<a href="#CD010764-tbl-0002">Table 2</a>) (<a href="./references#CD010764-bbs2-0063" title="DarouxM , PrévostG , Maillard‐LefebvreH , GaxatteC , D'AgatiVD , SchmidtAM , et al. Advanced glycation end‐products: implications for diabetic and non‐diabetic nephropathies. Diabetes and Metabolism2010;36:1‐10. ">Daroux 2010</a>; <a href="./references#CD010764-bbs2-0071" title="GeraldesP , KingGL . Activation of protein kinase C isoforms and its impact on diabetic complications. Journal of Circulation Research2010;106(8):1319‐31. ">Geraldes 2010</a>; <a href="./references#CD010764-bbs2-0072" title="GiaccoF , BrownleeM . Oxidative stress and diabetic complications. Circulation Research2010;107(9):1058‐70. ">Giacco 2010</a>; <a href="./references#CD010764-bbs2-0083" title="InzucchiSE , BergenstalRM , BuseJB , DiamantM , FerranniniE , NauckM , et al. Management of hyperglycemia in type 2 diabetes: a patient‐centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Journal of Diabetes Care2012;35(6):1364‐79. ">Inzucchi 2012</a>). A common list of glycaemic control medications used in diabetes management is shown in <a href="#CD010764-tbl-0003">Table 3</a>. Most guidelines recommend a glycaemic control target of 7% or lower for HbA1c (glycated haemoglobin) (<a href="#CD010764-tbl-0002">Table 2</a>). The revised guidelines of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend individualisation, with more stringent (6.5% or lower) or less stringent (8% or lower) HbA1c targets as appropriate for individuals (<a href="./references#CD010764-bbs2-0050" title="American Diabetes Association. Standards of medical care in diabetes 2012. Diabetes Care2012;35(Suppl 1):11‐63. ">ADA 2012</a>; <a href="./references#CD010764-bbs2-0058" title="CheungNW , ConnJJ , D'EmdenMC , GuntonJE , JenkinsAJ , RossGP , et al. Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Medical Journal of Australia2009;191:339–44. ">Cheung 2009</a>; <a href="./references#CD010764-bbs2-0083" title="InzucchiSE , BergenstalRM , BuseJB , DiamantM , FerranniniE , NauckM , et al. Management of hyperglycemia in type 2 diabetes: a patient‐centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Journal of Diabetes Care2012;35(6):1364‐79. ">Inzucchi 2012</a>). There is marked variation in the definition of intensive glycaemic control between guidelines and trials (<a href="./references#CD010764-bbs2-0074" title="HemmingsenB , LundSS , GluudC , VaagA , AlmdalT , HemmingsenC , et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta‐analysis and trial sequential analysis of randomised clinical trials. BMJ2011;343:d6898. ">Hemmingsen 2011a</a>). For the purposes of this review we included trials where an intervention has been performed with the aim of achieving improved glycaemic control in comparison to a conventional control group. </p> <div class="table" id="CD010764-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">HbA1c targets recommended by different international guidelines ª</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Guideline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Hba1c targets in adults</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Level of Evidence</b> </p> <p><b>(According to Oxford Centre for Evidence‐based Medicine ‐ Levels of Evidence (March 2009))</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Australia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>National Health and Medical Research Council/Diabetes Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australian Paediatric Endocrine Group/ Australian Diabetes Society</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade D</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>  UK</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>National Institute for Health and Care Excellence (NICE)</p> <p> </p> <p>‐ Managing type 1 DM diabetes in adults</p> <p> </p> <p>‐ Blood glucose lowering therapy for type 2 DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>2012</p> <p>  </p> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> ≤ 7.5% if increased arterial risk</p> <p>≤ 6.5%  Between 6.5% and 7.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade B</p> <p> </p> <p>Not reported</p> <p>  </p> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scottish Intercollegiate Guidelines Network (SIGN)</p> <p> ‐ Type 1  Diabetes</p> <p> ‐ Type 2 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>No set figure</p> <p> &lt; 7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Not reported</p> <p>Grade A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b> USA</b> </p> <p><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>National Clearinghouse</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 7% or individualize to a goal of &lt; 8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade B</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Diabetes Association</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 7% or individualise to a goal:</p> <p>&lt; 6.5%</p> <p>&lt; 8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade B</p> <p>Grade C</p> <p>Grade B</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American  Association of Clinical Endocrinologists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 6.5% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade D</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> International Diabetes Federation (IDF)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>International Diabetes Federation ‐ Global Guideline  for type 2 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 7.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U/K</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Canada</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canadian Diabetes Association</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 7%</p> <p>≤ 6.5% (may be considered to lower risk of nephropathy further)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade C, Level 3</p> <p>Grade A, Level 1A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Europe</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>European Association for the Study of Diabetes (EASD) and American Diabetes Association (ADA) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 7% or individualise to a goal of:</p> <p>6% to 6.5% (patients with short disease, duration, long life expectancy, no significant CVD) </p> <p>7.5% to8.0% (history of severe hypoglycaemia, limited life expectancy, advanced complications, extensive comorbid conditions and those in<br/> whom the target is difficult to attain) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> New Zealand</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New Zealand Group Guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade D</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ª Adapted from Australian Electronic Therapeutic Guidelines (<a href="./references#CD010764-bbs2-0067" title="ETG . Type 2 diabetes and cardiovascular disease risk. Australian Electronic Therapeutic Guidelines http://www.tg.org.au/etg_demo/phone/tgc/cvg/951.htm (accessed 10 December 2012). ">Electronic Therapeutic Guidelines Australia 2012</a>) </p> <p><b>Abbreviations</b> </p> <p>CVD = cerebrovascular disease<br/> DM = diabetes mellitus<br/> U/K = unknown </p> </div> </div> <div class="table" id="CD010764-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Commonly used medications in diabetes mellitus (type 1 and type 2) for the management of hyperglycaemia.</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Class/Drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Expected decrease in HbA1c</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> ORAL ANTIDIABETIC THERAPY </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfonylureas</p> <p> <ul id="CD010764-list-0012"> <li> <p>glibenclamide</p> </li> <li> <p>gliclazide</p> </li> <li> <p>glimepiride</p> </li> <li> <p>glipizide</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DPP‐4‐inhibitors</p> <p> <ul id="CD010764-list-0013"> <li> <p>sitagliptin</p> </li> <li> <p>vildagliptin,</p> </li> <li> <p>saxagliptin</p> </li> <li> <p>linagliptin</p> </li> <li> <p>anagliptin</p> </li> <li> <p>alogliptin</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% to 0.8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acarbose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% to 0.8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiazolidinedione (glitazones)</p> <p> <ul id="CD010764-list-0014"> <li> <p>pioglitazone</p> </li> <li> <p>rosglitazone</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% to 1.4%</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> PARENTERAL THERAPY</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GLP‐analogues</p> <p> <ul id="CD010764-list-0015"> <li> <p>exenatide</p> </li> <li> <p>liraglutide</p> </li> <li> <p>lixisenatide</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% to 1.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5% to 3.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Insulin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Generic name</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very‐short‐acting (rapid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aspart</p> <p>Glulisine</p> <p>Lispro</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐acting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neutral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate‐acting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Isophane (protamine suspension)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐acting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Determir</p> <p>Glargine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biphasic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neutral/isophane</p> <p>Lispro/lispro protamine</p> <p>Aspart/aspart protamine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Methods of insulin delivery</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p> <ul id="CD010764-list-0016"> <li> <p>Syringe</p> </li> <li> <p>Pen injector</p> </li> <li> <p>Pump/continuous subcutaneous insulin infusion</p> </li> </ul> </p> </td> </tr> </tbody> </table> </div> <p>Most of the current glycaemic targets for diabetes are based on several landmark trials that investigated the effects of intensive glycaemic control compared to conventional treatments (<a href="#CD010764-tbl-0002">Table 2</a>) (<a href="./references#CD010764-bbs2-0058" title="CheungNW , ConnJJ , D'EmdenMC , GuntonJE , JenkinsAJ , RossGP , et al. Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Medical Journal of Australia2009;191:339–44. ">Cheung 2009</a>; <a href="./references#CD010764-bbs2-0075" title="HemmingsenB , LundSS , GluudC , VaagA , AlmdalT , HemmingsenC , et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008143.pub2] ">Hemmingsen 2011b</a>; <a href="./references#CD010764-bbs2-0089" title="MacisaacRJ , JerumsG . Intensive glucose control and cardiovascular outcomes in type 2 diabetes. Heart, Lung and Circulation2011;20(10):647‐54. ">Macisaac 2011</a>; <a href="./references#CD010764-bbs2-0092" title="MazzoneT . Intensive glucose lowering and cardiovascular disease prevention in diabetes reconciling the recent clinical trial data. Circulation2010;122:2201‐11. ">Mazzone 2010</a>). The findings from these studies also illustrate the benefits and risks associated with intensive glycaemic control. Therefore, when investigating intensive glycaemic control as a potential intervention for diabetic foot ulcers, it is important to take into account the present literature underpinning current glycaemic management. </p> <p>Intensive glycaemic control implemented in the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) led to a reduction in the progression and development of microvascular (small vessel) complications including DPN (<a href="./references#CD010764-bbs2-0091" title="MattilaTK , DeBoerA . Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs2010;70(17):2229‐45. ">Mattila 2010</a>). The UKPDS demonstrated a 37% reduction in the risk of microvascular complications for each 1% decrease in HbA1c (95% confidence interval: 33% to 41%) (<a href="./references#CD010764-bbs2-0112" title="UKPDS . Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):837‐53. ">UKPDS 1998</a>; <a href="./references#CD010764-bbs2-0110" title="StrattonIM , AdlerAI , NeilAW , MatthewsDR , ManleySE , CullCA , et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ2000;321:405‐12. ">Stratton 2000</a>). Similarly, the ADVANCE trial found a 14% relative risk reduction for major microvascular events in the intensive control group when compared to the standard control group (9.4% versus 10.9%; hazard ratio (HR) 0.86; 95% CI: 0.77 to 0.97), although mainly in terms of reduced incidence of nephropathy (kidney disease) (<a href="./references#CD010764-bbs2-0051" title="ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. ">ADVANCE 2008</a>). </p> <p>A recent Cochrane review concluded that intensive glucose control reduced the risk of amputation by 36% in type 2 diabetes (relative risk (RR) 0.64, 95% CI: 0.43 to 0.95; 6960 participants in eight trials) (<a href="./references#CD010764-bbs2-0075" title="HemmingsenB , LundSS , GluudC , VaagA , AlmdalT , HemmingsenC , et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008143.pub2] ">Hemmingsen 2011b</a>). In addition there was an 11% relative risk reduction (RR 0.89, 95% CI: 0.83 to 0.95; 25,760 participants in four trials) and a 1% to 2% absolute risk reduction in composite microvascular outcomes in favour of intensive glycaemic control for all included trials (<a href="./references#CD010764-bbs2-0075" title="HemmingsenB , LundSS , GluudC , VaagA , AlmdalT , HemmingsenC , et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008143.pub2] ">Hemmingsen 2011b</a>). A number of meta‐analyses have demonstrated that the incidence of hypoglycaemia (low blood glucose) was increased during intensive glycaemic control, making this a significant adverse outcome (<a href="./references#CD010764-bbs2-0075" title="HemmingsenB , LundSS , GluudC , VaagA , AlmdalT , HemmingsenC , et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008143.pub2] ">Hemmingsen 2011b</a>; <a href="./references#CD010764-bbs2-0088" title="MaJ , YangW , FangN , ZhuW , WeiM . The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta‐analysis. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD2009;19(9):596‐603. ">Ma 2009</a>; <a href="./references#CD010764-bbs2-0091" title="MattilaTK , DeBoerA . Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs2010;70(17):2229‐45. ">Mattila 2010</a>). It must be noted that the beneficial effects on microvascular complications from using intensive glycaemic control took more than five years to emerge, and the benefits were less pronounced for people with advanced type 2 diabetes compared to those with new‐onset type 2 diabetes (<a href="./references#CD010764-bbs2-0075" title="HemmingsenB , LundSS , GluudC , VaagA , AlmdalT , HemmingsenC , et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008143.pub2] ">Hemmingsen 2011b</a>; <a href="./references#CD010764-bbs2-0091" title="MattilaTK , DeBoerA . Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs2010;70(17):2229‐45. ">Mattila 2010</a>). Despite this, data on retinopathy (disease of the retina) suggest that people with the advanced stages of type 2 diabetes may also benefit from intensive glycaemic control (<a href="./references#CD010764-bbs2-0074" title="HemmingsenB , LundSS , GluudC , VaagA , AlmdalT , HemmingsenC , et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta‐analysis and trial sequential analysis of randomised clinical trials. BMJ2011;343:d6898. ">Hemmingsen 2011a</a>). The effects of intensive glycaemic control in people with type 1 diabetes demonstrated in the DCCT were still evident after 14 years of follow‐up (i.e. long after the intervention was completed), and that phenomenon had been termed 'glycaemic memory' (<a href="./references#CD010764-bbs2-0072" title="GiaccoF , BrownleeM . Oxidative stress and diabetic complications. Circulation Research2010;107(9):1058‐70. ">Giacco 2010</a>). More recent data suggested that glycaemic memory also occurred in people with type 2 diabetes, where it is termed the 'legacy effect', whereby the benefits of earlier interventions were still evident later on in the disease course (<a href="./references#CD010764-bbs2-0072" title="GiaccoF , BrownleeM . Oxidative stress and diabetic complications. Circulation Research2010;107(9):1058‐70. ">Giacco 2010</a>). </p> <p>While intensive therapy, with the goal of achieving near normal HbA1c levels (7%), has altered the clinical course of nephropathy, neuropathy and retinopathy, the majority of studies have not examined the benefits of intensive therapy when implemented after the onset of late diabetes complications, such as diabetic foot ulcers (<a href="./references#CD010764-bbs2-0094" title="NathanDM . Understanding the long‐term benefits and dangers of intensive therapy of diabetes. Archives of Internal Medicine2012;172(10):769‐70. ">Nathan 2012</a>). </p> </section> <section id="CD010764-sec-0025"> <h3 class="title" id="CD010764-sec-0025">How the intervention might work</h3> <p>Optimum healing of a foot ulcer requires a well‐orchestrated integration of molecular and biological events including cell migration, proliferation, extracellular matrix deposition and remodelling, which is hindered by the effects of hyperglycaemia (<a href="./references#CD010764-bbs2-0069" title="FalangaV . Wound healing and its impairment in the diabetic foot. The Lancet2005;366(9498):1736–43. ">Falanga 2005</a>; <a href="./references#CD010764-bbs2-0098" title="RafehiH , El‐OstaA , KaragiannisTC . Genetic and epigenetic events in diabetic wound healing. International Wound Journal2010;8(1):12‐21. ">Rafehi 2010</a>). Hyperglycaemia has been associated with delayed healing of foot ulcers (<a href="./references#CD010764-bbs2-0057" title="Korzon‐BurakowskaA , EdmondsM . Role of the microcirculation in diabetic foot ulceration. International Journal of Lower Extremity Wounds2006;5(3):144‐8. ">Burakowska 2006</a>; <a href="./references#CD010764-bbs2-0059" title="ChristmanAL , SelvinE , MargolisDJ , LazarusGS , GarzaLA . Hemoglobin A1c predicts healing rate in diabetic wounds. Journal of Investigative Dermatology2011;131(10):2121‐7. ">Christman 2011</a>; <a href="./references#CD010764-bbs2-0062" title="D'SouzaDR , SalibMM , BennettJ , Mochin‐PetersM , AsraniK , GoldblumSE , et al. Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway. Journal of Biological Chemistry2009;284(27):17947‐55. ">D'Souza 2009</a>; <a href="./references#CD010764-bbs2-0069" title="FalangaV . Wound healing and its impairment in the diabetic foot. The Lancet2005;366(9498):1736–43. ">Falanga 2005</a>; <a href="./references#CD010764-bbs2-0098" title="RafehiH , El‐OstaA , KaragiannisTC . Genetic and epigenetic events in diabetic wound healing. International Wound Journal2010;8(1):12‐21. ">Rafehi 2010</a>). Interventions that target improvements in glycaemic control are thus of potential benefit. Delayed healing of foot ulcers appears to be the net result of both microvascular and macrovascular disease (<a href="./references#CD010764-bbs2-0057" title="Korzon‐BurakowskaA , EdmondsM . Role of the microcirculation in diabetic foot ulceration. International Journal of Lower Extremity Wounds2006;5(3):144‐8. ">Burakowska 2006</a>; <a href="./references#CD010764-bbs2-0066" title="DinhTL , VevesA . A review of the mechanisms implicated in the pathogenesis of the diabetic foot. International Journal of Lower Extremity Wounds2005;4(3):154‐9. ">Dinh 2005</a>). Well‐orchestrated wound healing is essential for tissue replacement and restoration, and generally involves three main phases: acute inflammation, proliferation, and remodelling (<a href="./references#CD010764-bbs2-0098" title="RafehiH , El‐OstaA , KaragiannisTC . Genetic and epigenetic events in diabetic wound healing. International Wound Journal2010;8(1):12‐21. ">Rafehi 2010</a>). In contrast, diabetic foot ulcers do not follow the orderly process of wound healing and differ at a molecular level in terms of expression of growth factors, cytokines and proteins (<a href="./references#CD010764-bbs2-0066" title="DinhTL , VevesA . A review of the mechanisms implicated in the pathogenesis of the diabetic foot. International Journal of Lower Extremity Wounds2005;4(3):154‐9. ">Dinh 2005</a>; <a href="./references#CD010764-bbs2-0098" title="RafehiH , El‐OstaA , KaragiannisTC . Genetic and epigenetic events in diabetic wound healing. International Wound Journal2010;8(1):12‐21. ">Rafehi 2010</a>). These processes are known to be affected by hyperglycaemia. </p> <p>Several proposed pathogenic pathways exist to explain the adverse effects of hyperglycaemia (<a href="./references#CD010764-bbs2-0071" title="GeraldesP , KingGL . Activation of protein kinase C isoforms and its impact on diabetic complications. Journal of Circulation Research2010;106(8):1319‐31. ">Geraldes 2010</a>). These include: 1) activation of the polyol pathway; 2) non‐enzymatic glycosylation and formation of advanced glycation end products (AGEs); 3) activation of the diacylglycerol‐ (DAG) protein kinase C pathway; and 4) overactivity of the hexosamine pathway (<a href="./references#CD010764-bbs2-0056" title="BrownleeM . The pathobiology of diabetic complications. A unifying mechanism. Diabetes2004;54(6):1615‐25. ">Brownlee 2004</a>; <a href="./references#CD010764-bbs2-0071" title="GeraldesP , KingGL . Activation of protein kinase C isoforms and its impact on diabetic complications. Journal of Circulation Research2010;106(8):1319‐31. ">Geraldes 2010</a>; <a href="./references#CD010764-bbs2-0072" title="GiaccoF , BrownleeM . Oxidative stress and diabetic complications. Circulation Research2010;107(9):1058‐70. ">Giacco 2010</a>; <a href="./references#CD010764-bbs2-0073" title="GuptaSK , PandaS , SinghSK . The etiopathogenesis of the diabetic foot: an unrelenting epidemic. The International Journal of Lower Extremity Wounds2010;9(3):127–31. ">Gupta 2010</a>). All four mechanisms have been linked to a single, unified preceding event, namely mitochondrial overproduction of reactive oxygen species (ROS) (<a href="./references#CD010764-bbs2-0056" title="BrownleeM . The pathobiology of diabetic complications. A unifying mechanism. Diabetes2004;54(6):1615‐25. ">Brownlee 2004</a>). ROS are known to promote cellular dysfunction through damage to DNA synthesis, oxidation of lipids and amino acids and inactivation of key enzymes involved in metabolic function, which are implicated in the formation of diabetic foot ulcers. Hyperglycaemia also promotes endothelial dysfunction, vascular leakage and impaired angiogenesis (formation of new blood vessels) originating from the above mentioned pathways, and leads to activation of the inflammatory response via activation of nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) (<a href="./references#CD010764-bbs2-0062" title="D'SouzaDR , SalibMM , BennettJ , Mochin‐PetersM , AsraniK , GoldblumSE , et al. Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway. Journal of Biological Chemistry2009;284(27):17947‐55. ">D'Souza 2009</a>; <a href="./references#CD010764-bbs2-0072" title="GiaccoF , BrownleeM . Oxidative stress and diabetic complications. Circulation Research2010;107(9):1058‐70. ">Giacco 2010</a>). The incidence of infection is also increased in people with diabetes and immunological disturbances, such as deficiencies in polymorphonuclear leukocyte, monocyte and macrophage (types of white blood cell) function have been noted during hyperglycaemia (<a href="./references#CD010764-bbs2-0065" title="DelamaireM , MaugendreD , MorenoM , LeGoffMC , AllannicH , GenetetB . Impaired leucocyte functions in diabetic patients. Diabetic Medicine1997;14(1):29‐34. ">Delamaire 1997</a>; <a href="./references#CD010764-bbs2-0108" title="StegengaME , Van derCrabbenSN , BlümerRM , LeviM , MeijersJC , SerlieMJ , et al. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood2008;112(1):82‐9. ">Stegenga 2008</a>).  All these factors, which are a consequence of hyperglycaemia, may play a role in delayed healing of foot ulcers. </p> <p>A recent observational study showed that HbA1c was an important clinical predictor of the rate of wound healing; with each 1% increase in HbA1c level associated with a decrease in the wound healing rate of 0.028 cm² per day (95% CI: 0.003 to 0.054) (<a href="./references#CD010764-bbs2-0059" title="ChristmanAL , SelvinE , MargolisDJ , LazarusGS , GarzaLA . Hemoglobin A1c predicts healing rate in diabetic wounds. Journal of Investigative Dermatology2011;131(10):2121‐7. ">Christman 2011</a>). Despite this, the effects of short‐term reduction in HbA1c did not appear to have any effect on endothelial function in patients with type 2 diabetes with a history of poor glycaemic control (<a href="./references#CD010764-bbs2-0054" title="BaggW , WhalleyGA , GambleG , DruryPL , SharpeN , BraatvedtGD . Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. Internal Medicine Journal2001;31(6):322‐8. ">Bagg 2001</a>). Therefore, there remains a clear need to document benefits associated with improved glycaemic control in people with diabetic foot ulcers. While chronic complications of diabetes such as DPN and PAD maybe difficult to reverse, it can be postulated that aspects of ulcer healing relating to immunological and connective tissue function may be more amenable to improvement if normoglycaemia (normal level of glucose in blood) is achieved (<a href="./references#CD010764-bbs2-0084" title="JeffcoateWJ , PriceP , HardingKG , International Working Group on Wound Healing and Treatments for People with Diabetic Foot Ulcers. Wound healing and treatments for people with diabetic foot ulcers. Diabetes/Metabolism Research and Reviews2004;20(Suppl 1):S78‐89. ">Jeffcoate 2004</a>). </p> </section> <section id="CD010764-sec-0026"> <h3 class="title" id="CD010764-sec-0026">Why it is important to do this review</h3> <p>Foot ulcers continue to be a significant burden for people with diabetes, their caregivers and the healthcare system (<a href="./references#CD010764-bbs2-0102" title="SchaperNC . Lessons from Eurodiale. Diabetes/Metabolism Research and Reviews2012;28(Suppl 1):21‐6. ">Schaper 2012</a>). The outcome of a foot ulcer in people with diabetes should not only be viewed from a clinical perspective (e.g. healing or amputation), but also from an individual and socioeconomic perspective. Health‐related quality of life (HRQoL) is significantly reduced in people with diabetes, and further impaired by the presence of foot disease, whilst it is improved with foot ulcer healing (<a href="./references#CD010764-bbs2-0080" title="HoggFR , PeachG , PriceP , ThompsonMM , HinchliffeRJ . Measures of health‐related quality of life in diabetes‐related foot disease: a systematic review. Diabetologia2012;55(3):552‐65. ">Hogg 2012</a>). Healthcare costs associated with foot ulcers and amputations contribute significantly to the financial burden of diabetes (<a href="./references#CD010764-bbs2-0086" title="JonesRN , MarshallWP . Does the proximity of an amputation, length of time between foot ulcer development and amputation, or glycemic control at the time of amputation affect the mortality rate of people with diabetes who undergo an amputation?. Advances in Skin &amp; Wound Care2008;21(3):118‐23. ">Jones 2008</a>). In the United States in 2008, the total number of discharges attributed to diabetes‐related amputations was 45,000. The average length of stay was 10.1 days and the in‐hospital mortality proportion was 1.29% (<a href="./references#CD010764-bbs2-0061" title="CookJJ , SimonsonDC . Epidemiology and health care cost of diabetic foot problems. In: VevesA editor(s). The Diabetic Foot: Medical and Surgical Management. Boston: Contemporary Diabetes, 2012:17‐32. ">Cook 2012</a>). The mean hospital charges were USD 56,216 per patient and the estimated aggregate cost for the year 2008 was USD 2,548,319,965 (<a href="./references#CD010764-bbs2-0061" title="CookJJ , SimonsonDC . Epidemiology and health care cost of diabetic foot problems. In: VevesA editor(s). The Diabetic Foot: Medical and Surgical Management. Boston: Contemporary Diabetes, 2012:17‐32. ">Cook 2012</a>). </p> <p>Therefore, foot ulceration in people with diabetes has substantial socioeconomic, quality‐of‐life, and healthcare implications, and it is imperative that all efforts be made to prevent and treat the burden of foot ulceration in order to reduce amputation rates ‐ as highlighted by the St Vincent Declaration in 1989 (<a href="./references#CD010764-bbs2-0070" title="GameF . Choosing life or limb. Improving survival in the multi‐complex diabetic foot patient. Diabetes/Metabolism Research and Reviews2012;28(Suppl 1):97‐100. ">Game 2012</a>). Advances in the treatment of diabetic foot ulcers are promising, however the intrinsic pathophysiological abnormalities of hyperglycaemia that lead to ulceration and delayed ulcer healing cannot be ignored (<a href="./references#CD010764-bbs2-0069" title="FalangaV . Wound healing and its impairment in the diabetic foot. The Lancet2005;366(9498):1736–43. ">Falanga 2005</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010764-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010764-sec-0027">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010764-sec-0087">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010764-sec-0027"></div> <p>To assess the effects of intensive glycaemic control compared with conventional control on the outcome of foot ulcers in people with type 1 and type 2 diabetes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010764-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010764-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010764-sec-0088">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010764-sec-0028"></div> <section id="CD010764-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010764-sec-0030"> <h4 class="title">Types of studies</h4> <p>We considered randomised controlled trials (RCTs) for inclusion where they investigated the effects of intensive glycaemic control on the outcome of active foot ulcers in people with diabetes. We excluded non‐randomised and quasi‐experimental trials. </p> </section> <section id="CD010764-sec-0031"> <h4 class="title">Types of participants</h4> <p>Men and women (over 18 years) diagnosed with type 1 or type 2 diabetes by clearly‐defined, accepted standards relevant to the time of the study, with an active foot ulcer that had any of the following aetiologies (causes):        </p> <p> <ul id="CD010764-list-0017"> <li> <p>neuropathic, or       </p> </li> <li> <p>neuro‐ischaemic, or </p> </li> <li> <p>ischaemic, with or without</p> </li> <li> <p>infection (as clinically or diagnostically documented by laboratory analysis).</p> </li> </ul> </p> <p>For the purposes of this review, venous ulcers, malignant ulcers and post‐surgical ulcers were excluded. </p> </section> <section id="CD010764-sec-0032"> <h4 class="title">Types of interventions</h4> <p>We planned to include trials that had assessed any intervention that aimed to achieve a lower glycaemic target in a diabetes group (i.e. near normal glycaemic levels) when compared to a control group with a higher glycaemic target. The latter group was defined as the 'conventional' group. Therefore the intensive group would have had a lower glycaemic target level compared to the conventional group in the trial. </p> <p>Therefore, we sought to include any intervention that had:</p> <p> <ul id="CD010764-list-0018"> <li> <p>attempted to maintain or control blood glucose levels and measured changes in markers of glycaemic control (HbA1c or fasting, random, mean plasma glucose, home capillary or urine glucose), and </p> </li> <li> <p>documented the effect of these interventions on active foot ulcer outcomes.</p> </li> </ul> </p> <p>Allowable interventions included subcutaneous insulin administration, continuous subcutaneous insulin infusion using an insulin pump or oral anti‐diabetes agents or a combination of both, or any lifestyle interventions or both (<a href="#CD010764-tbl-0004">Table 4</a>). The overall definition of the interventional (intensive) group was that it should have a lower glycaemic target than the comparison (conventional) group. </p> <div class="table" id="CD010764-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Alternative treatments for lowering blood glucose in people with diabetic foot ulcers</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Nature of intervention</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Exercise </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Psychological and behavioural </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Dietary </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any exercise intervention that has the primary aim of improving glycaemic control in people with diabetes, where the impact of the intervention on glycaemic control and changes in an active foot ulcer has been documented </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any psychological or behavioural intervention that has the primary aim of improving glycaemic control in people with diabetes, where the impact of the intervention on glycaemic control and the resultant changes in a foot ulcer has been documented </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any dietary or nutritional intervention that has the primary aim of improving glycaemic control in people with diabetes, where the changes in glycaemic control have been correlated with changes in active foot ulcer outcome </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Examples</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exercise programmes of any intensity and duration that had the primary aim of improvement in glycaemic control </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Frequent checking of blood glucose levels, interventions aimed at good pharmaceutical practice (i.e. improving compliance with medication) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Healthy eating programmes, dietary or nutritional supplements</p> </td> </tr> </tbody> </table> </div> <p>Pharmaceutical treatments included any route of administration, dose, duration or frequency of insulin or other pharmaceutical agents, or both. </p> </section> <section id="CD010764-sec-0033"> <h4 class="title">Types of outcome measures</h4> <section id="CD010764-sec-0034"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010764-list-0019"> <li> <p>Number of ulcers healed.</p> </li> <li> <p>Time to complete ulcer healing.</p> </li> <li> <p>Change in ulcer severity reported as a change in an ulcer grading score using a well‐defined validated ulcer grading scale e.g. University of Texas Wound Classification System (UTWCS) that measures the depth, presence of infection and ischemia of an ulcer (<a href="./references#CD010764-bbs2-0053" title="ArmstrongD , LaveryDC , HarklessL . Validation of a diabetic wound classification system ‐ the contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care1998;21(5):855‐9. ">Armstrong 1998</a>). </p> </li> <li> <p>Incidence of amputation related to foot ulcers (identified on International Classification of Disease (ICD) codes (<a href="./references#CD010764-bbs2-0095" title="National Centre for Classification in Health. The Australian Classification of Health Interventions (ACHI) 5th edition: tabular list of Interventions and alphabetic index of interventions. The University of Sydney, Faculty of Health Sciences2006. ">NCCH 2006</a>). </p> </li> </ul> </p> </section> <section id="CD010764-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010764-list-0020"> <li> <p>New ulcer development (recurrence of an ulcer or initiation of a new ulcer).</p> </li> <li> <p>Proportion of infected ulcers at study completion.</p> </li> <li> <p>Adverse events: adverse events were to be noted from each individual trial, and, where trial reports were based on a sound methodology with standardised approach to detect and assess adverse events, these were to be included in any potential analysis and judged on a case‐by‐case basis. Treatment‐focused examples included: adverse drug reaction requiring hospitalisation; weight gain; and hypoglycaemia. Disease‐focused examples included: worsening of neuropathy (clinically or using a validated neuropathy score); development or worsening of PAD (clinically or by diagnostic measurement such as ankle brachial index (ABI); gangrene; congestive heart failure; chronic kidney disease (CKD) (stages 1‐5); dialysis; retinopathy and documented diabetic ketoacidosis (DKA); hyperosmolar hyperglycaemic state, hyperglycaemia; and lactic acidosis. </p> </li> <li> <p>Effect on HRQoL: As measured by a validated quality of life (QOL) measurement tool that is disease‐specific to foot ulcers or generic to QOL or both. </p> </li> <li> <p>Cost of intervention compared to conventional treatment, including: direct medical costs; direct non‐medical costs (e.g. transport, assistive devices); indirect costs (e.g. sick leave, reduced productivity, early retirement and premature death); disability‐adjusted life years (DALY); and years of life lost (YLL). </p> </li> <li> <p>All‐cause mortality.</p> </li> </ul> </p> </section> </section> </section> <section id="CD010764-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010764-sec-0037"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases to identify reports of relevant randomised clinical trials: </p> <p> <ul id="CD010764-list-0021"> <li> <p>The Cochrane Wounds Specialised Register; (searched 7 December 2015);</p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2015, Issue 11); </p> </li> <li> <p>Ovid MEDLINE (1946 to 7 December 2015);</p> </li> <li> <p>Ovid MEDLINE (In‐Process &amp; Other Non‐Indexed Citations) (searched 7 December 2015);</p> </li> <li> <p>Ovid EMBASE (1974 to 7 December 2015);</p> </li> <li> <p>EBSCO CINAHL Plus (1937 to 7 December 2015);</p> </li> <li> <p>Elsevier SCOPUS (1960 to 13 December 2015);</p> </li> <li> <p>ISI Web of Knowledge Web of Science (1965 to 13 December 2015);</p> </li> <li> <p>BioMed Central (1997 to 13 December 2015);</p> </li> <li> <p>LILACS (1995 to 13 December 2015).</p> </li> </ul> </p> <p>We used the following search strategy in The Cochrane Central Register of Controlled Trials (CENTRAL): </p> <p>#1 MeSH descriptor: [Blood Glucose] explode all trees<br/> #2 MeSH descriptor: [Hypoglycemic Agents] explode all trees<br/> #3 MeSH descriptor: [Hyperglycemia] explode all trees<br/> #4 MeSH descriptor: [Hypoglycemia] explode all trees<br/> #5 MeSH descriptor: [Insulin] explode all trees<br/> #6 MeSH descriptor: [Metformin] explode all trees<br/> #7 MeSH descriptor: [Thiazolidinediones] explode all trees<br/> #8 MeSH descriptor: [alpha‐Glucosidases] explode all trees<br/> #9 MeSH descriptor: [Glucagon‐Like Peptide 1] explode all trees<br/> #10 MeSH descriptor: [Acarbose] explode all trees<br/> #11 (blood glucose):ti,ab,kw<br/> #12 (((glycaemic or glycemic) next control) or "intensive glucose control"):ti,ab,kw<br/> #13 ((hypoglycaemi* or hypoglycemi*) next (agent* or drug*)):ti,ab,kw<br/> #14 (oral next (hypoglycaemi* or hypoglycemi*)):ti,ab,kw<br/> #15 ("fasting glucose" or "glucose target"):ti,ab,kw<br/> #16 ((anti‐diabetes next medication*) or (diabetes next medication*) or insulin* or sulphonyureas or metformin or thiazolidinedione* or DPP‐4 inhibitor* or glitinide or (glucosidase next inhibitor*) or biguinide or "GLP‐1 agonist" or acarbose or (incretin next enhancer*) or (incretin next mimetic*) or HbA1c):ti,ab,kw<br/> #17 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #13 or #14 or #15 or #16<br/> #18 MeSH descriptor: [Foot Ulcer] explode all trees<br/> #19 MeSH descriptor: [Diabetic Foot] explode all trees<br/> #20 (diabet* near/3 ulcer*):ti,ab,kw<br/> #21 (diabet* near/3 (foot or feet)):ti,ab,kw<br/> #22 (diabet* near/3 wound*):ti,ab,kw<br/> #23 (diabet* near/3 defect*):ti,ab,kw<br/> #24 ("foot gangrene" or amputat*):ti,ab,kw<br/> #25 #18 or #19 or #20 or #21 or #22 or #23 or #24<br/> #26 #17 and #25 </p> <p>The search strategies were adapted for Ovid MEDLINE, Ovid EMBASE, EBSCO CINAHL and can be found in <a href="./appendices#CD010764-sec-0069">Appendix 2</a>. We combined the Ovid MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity‐ and precision‐maximising version (2008 revision) (<a href="./references#CD010764-bbs2-0087" title="LefebvreC , ManheimerE , GlanvilleJ , on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>). We combined the EMBASE search with the Ovid EMBASE filter developed by the UK Cochrane Centre (<a href="./references#CD010764-bbs2-0087" title="LefebvreC , ManheimerE , GlanvilleJ , on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>). We combined the CINAHL searches with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<a href="./references#CD010764-bbs2-0106" title="Scottish Intercollegiate Guidelines Network (SIGN). Search filters. http://www.sign.ac.uk/methodology/filters.html#random (accessed 10 December 2012). ">SIGN 2012</a>). We did not restrict studies with respect to language, date of publication or study setting. </p> <p>Searches of the Cochrane Wounds Specialised Register, CENTRAL, MEDLINE, EMBASE and CINAHL were carried out at Cochrane Wounds editorial base. We modified the original search strategy shown above to search the SCOPUS, Biomed Central, Web of Science and LILACS databases. </p> <p>We also searched the following ongoing trial databases for relevant published, non‐published, ongoing and terminated clinical trials: </p> <p> <ul id="CD010764-list-0022"> <li> <p>EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/index.html" target="_blank">https://www.clinicaltrialsregister.eu/index.html</a>) (last searched 7 December 2015); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">http://www.clinicaltrials.gov/</a>); (last searched 7 December 2015); </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/en/" target="_blank">http://www.who.int/ictrp/en/</a>) (last searched 7 December 2015); </p> </li> <li> <p>Current Controlled Trials (<a href="http://www.controlled-trials.com" target="_blank">http://www.controlled‐trials.com</a>) (last searched 7 December 2015). </p> </li> </ul> </p> <p>We searched the pharmaceutical trials databases listed below (known pharmaceutical companies involved in manufacturer of diabetes medication) for relevant published, non‐published, ongoing and terminated clinical trials: </p> <p> <ul id="CD010764-list-0023"> <li> <p>AstraZeneca Clinical Trials web site (<a href="http://www.astrazenecaclinicaltrials.com" target="_blank">www.astrazenecaclinicaltrials.com</a>) (last searched 7 December 2015); </p> </li> <li> <p>Eli Lilly and Company Clinical Trial Registry (<a href="http://www.lillytrials.com" target="_blank">www.lillytrials.com</a>) (last searched 7 December 2015); </p> </li> <li> <p>Novartis (<a href="https://www.novartisclinicaltrials.com/TrialConnectWeb/home.nov" target="_blank">https://www.novartisclinicaltrials.com/TrialConnectWeb/home.nov</a>) (last searched 7 December 2015); </p> </li> <li> <p>Novo Nordisk (<a href="http://www.novonordisk-trials.com/WebSite/Search/Default.aspx" target="_blank">http://www.novonordisk‐trials.com/WebSite/Search/Default.aspx</a>) (last searched 7 December 2015); </p> </li> <li> <p>MSD (<a href="http://www.msd-australia.com.au/research/discoveryanddevelopment/pages/clinicaldevelopment/" target="_blank">http://www.msd‐australia.com.au/research/discoveryanddevelopment/pages/clinicaldevelopment/</a>l) (last searched 7 December 2015); </p> </li> <li> <p>Servier (<a href="http://www.servier.co.uk/content/clinical-trials" target="_blank">http://www.servier.co.uk/content/clinical‐trials</a>) (last searched 7 December 2015). </p> </li> </ul> </p> <p>For completeness, we searched through any clinical guidelines produced by the Joanna Briggs Institute, the National Institute for Health and Care Excellence (NICE), the National Health Service (NHS), the National Health and Medical Research Council (NHMRC) Australia, the Scottish Intercollegiate Guidelines Network (SIGN), National Clearinghouse and the International Working Group on the Diabetic Foot for any studies or publications of relevance that had not been identified through other search options. </p> <p>Where translation(s) were required, we contacted the original trial authors first to acquire an English language version of the manuscript. If the authors were not able to provide an English version, or where we did not receive any correspondence back from the authors, the articles were translated to English using translation services from our institution and then the authors were contacted again to clarify our understanding of the study. If the authors were unable to clarify the data, we planned to still attempt to use the trial. </p> </section> <section id="CD010764-sec-0038"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all full‐text articles considered for inclusion for any further studies of relevance.We contacted key local and international pharmaceutical groups regarding any unpublished trials. We also contacted several leading academics, clinicians and researchers in the area of diabetes management for information about any prospective or past studies not identified by the literature searches. </p> </section> </section> <section id="CD010764-sec-0039"> <h3 class="title" id="CD010764-sec-0039">Data collection and analysis</h3> <section id="CD010764-sec-0040"> <h4 class="title">Selection of studies</h4> <p>All review authors participated in the title and abstract screening of the search results. Two review authors (MF and RS) retrieved and assessed articles for inclusion independently using the following selection criteria. Included studies needed to: </p> <p> <ul id="CD010764-list-0024"> <li> <p>investigate changes in the glycaemic state of participants with type 1 or type 2 diabetes via changes in markers of glycaemic control (HbA1c or fasting, random, mean plasma glucose, home capillary or urine glucose), and </p> </li> <li> <p>report foot ulcer outcomes.</p> </li> </ul> </p> <p>We obtained full‐text publications of all articles meeting these selection criteria, or abstracts where these criteria could not be determined, and excluded any articles that we deemed not to be suitable (exclusion after screening of full text). Three third parties (JG, KS, YT) resolved any differences in opinion regarding whether to include or exclude a study. If no resolution was achieved, we contacted the original authors of the study for further clarification. We held team meetings when there was a need to make a final decision on inclusion. The PRISMA flow diagram in <a href="#CD010764-fig-0001">Figure 1</a> shows the study selection process (<a href="./references#CD010764-bbs2-0093" title="MoherD , LiberatiA , TetzlaffJ , Altman DG for the PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. BMJ2009;339:332‐6. [DOI: 10.1371/journal.pmed.1000097] ">Moher 2009</a>), and the <a href="./references#CD010764-bbs1-0002" title="">Excluded studies</a> table shows the reasons for exclusion for all the excluded trials. All citations were managed using Endnote version 5.1 (<a href="./references#CD010764-bbs2-0068" title="Endnote. http://endnote.com/. Thomson Reuters, 2012. ">Endnote 2012</a>). </p> <div class="figure" id="CD010764-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram." data-id="CD010764-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010764.pub2/media/CDSR/CD010764/image_n/nCD010764-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> </div> </section> <section id="CD010764-sec-0041"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MF and RS) would have independently extracted data, with a third and fourth review author (MC and PB) resolving any disagreements. We planned to enter data into a structured electronic data format, using the Cochrane Wounds extraction form to collect and organise data.This included information concerning: </p> <p> <ul id="CD010764-list-0025"> <li> <p>general information about the study (i.e. location, setting, aims);</p> </li> <li> <p>study eligibility;</p> </li> <li> <p>characteristics of study methods;</p> </li> <li> <p>participants;</p> </li> <li> <p>intervention groups;</p> </li> <li> <p>outcomes;</p> </li> <li> <p>'risk of bias' assessment;</p> </li> <li> <p>subgroup analyses</p> </li> </ul> </p> <p>The data to be extracted also included information on participant characteristics, study design, interventions utilised, outcomes assessed, and adverse events. MF and RS independently extracted all ongoing trial information and reported and compared it in appropriate Tables. </p> <p>Dealing with duplicate publications</p> <p>When more than one publication was found for a study, we evaluated all publications together to extract the maximum amount of relevant information. We resolved any discrepancies between the studies by contacting the study authors. If there were repeated observations of the same participants, we planned to use the longest follow‐up period for defining outcome measures of the study. </p> </section> <section id="CD010764-sec-0042"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We planned to assess risk of bias using the guidelines provided in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD010764-bbs2-0077" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We would have rated risk of bias as low, high or unclear in nature (<a href="./references#CD010764-bbs2-0077" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>), and planned to include a 'risk of bias' graph and 'risk of bias' summary. Two review authors (MF and RS) were to assess each study independently looking at he following criteria: </p> <p> <ul id="CD010764-list-0026"> <li> <p>sequence generation (confounding);</p> </li> <li> <p>allocation concealment (information bias): we planned to summarise how allocation sequences were generated and to report any attempts to conceal allocation of assigned intervention, along with any judgements concerning the risk of bias that may have arisen from the methods used; </p> </li> <li> <p>blinding for participants, personnel and outcome assessment (performance and detection bias): a brief summary of who was blinded or masked during the conduct and analysis of the studies; </p> </li> <li> <p>incomplete outcome data (attrition or selection bias): review authors' concerns over exclusion of participants and excessive (or differential) drop‐out rates; </p> </li> <li> <p>selective reporting (reporting bias): we would have summarised any concerns over the selective availability of data, including evidence of selective reporting of outcomes, time‐points, subgroups or analyses; </p> </li> <li> <p>other bias(es) identified.</p> </li> </ul> </p> <p>We planned to present a 'risk of bias' summary figure, which represents all bias assessment points in a table format. </p> </section> <section id="CD010764-sec-0043"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we planned to present results as summary risk ratios (RR) with 95% confidence intervals (CI). For continuous data, when outcomes were measured the same way in different trials, we planned to use the mean difference (MD). We planned to use the standardised mean difference to combine trials that measured the same outcome, but used different methods of measurement (SMD). Time to complete wound healing was time‐to‐event data. It was proposed that the most appropriate way of summarising it was to use methods of survival analysis and to express the intervention effect as a hazard ratio. It is not appropriate to analyse time‐to‐event data using methods used for continuous outcomes (e.g. using mean times‐to‐event), as the relevant times were only known for the subset of participants who have had the event. Censored participants were to be excluded, which, almost certainly, would have introduced bias. We planned to discuss time‐to‐event data that had been presented incorrectly as continuous data narratively, rather than as an analysis (<a href="./references#CD010764-bbs2-0064" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> <section id="CD010764-sec-0044"> <h4 class="title">Unit of analysis issues</h4> <p>We planned to identify the unit of analysis used in each individual study in relation to a wound, a foot, a participant or as multiple wounds on the same participant. We would have recorded if studies had incorrectly treated multiple wounds on a participant as being independent, rather than using within‐patient analysis methods, in the risk of bias assessment. For wound healing and amputation, unless otherwise stated, where the number of wounds appeared to equal the number of participants, we would have treated the wound as the unit of analysis. We planned to treat these studies with caution. We planned to include them in the systematic review, but to conduct meta‐analysis with and without them in sensitivity analyses, to assess the effect they would have had on the results. We also planned to assess the level of randomisation of each trial to see whether the number of observations matched the number of units randomised. Where the unit of analysis was unclear, we would have contacted the trial author for results per person. </p> <p>We planned to assess the unit of analysis for adverse event data on a trial‐by‐trial basis to establish whether the data were at participant level, or whether multiple events per participant were possible. Where the latter was the case, although the data could be reported on a trial by trial basis, they could not be analysed further without violating assumptions of independence. We planned to discuss the method of data collection, potential risks of measurement and performance biases, as well as the unit of analysis of adverse event data in detail in the review. </p> <p>If multiple treatment arms were reported, we planned to carry out multiple meta‐analyses. If more than one control group was used or where a single 'conventional' control group was not recognisable, we planned to combine all control group results and carry out pooled analyses of all control groups against the intervention group. </p> <p>In relation to the inclusion of cluster RCTs, we planned to attempt analysis where relevant information was available (i.e. the number, or mean size, of clusters, outcome data for total individuals with events, and an estimate of the intra‐cluster/intra‐class correlation coefficient (ICC). A more reliable analysis was then going to be conducted by reducing the size of each trial to its effective sample size using the design effect of a cluster RCT, and the standard error obtained from confidence intervals, as recommended by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010764-bbs2-0078" title="HigginsJPT , DeeksJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). Potential meta‐analysis could therefore have been performed using the inflated variances. </p> </section> <section id="CD010764-sec-0045"> <h4 class="title">Dealing with missing data</h4> <p>We planned to seek missing information from the original trial authors by emailing the contact person for the published studies. In particular, we would have contacted the authors for the relevant data where the reported findings of a study extended beyond foot ulcers and it would have been difficult to determine which, if any, findings related to foot ulcers specifically. When responses were not received, we were to contact additional authors from the publication. To avoid overly positive answers and the risk of false information, we planned to use open‐ended questions for contacting authors (<a href="./references#CD010764-bbs2-0078" title="HigginsJPT , DeeksJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). If information relating to outcomes (according to outcome measures) was missing, we deemed the article unsuitable for the review. </p> <p>Multiple efforts were made to acquire any missing data from authors. We planned to inspect factors such as attrition rates, drop‐out rates, randomised and included subject numbers, as well as numbers for intention‐to‐treat, treated‐per‐protocol and losses to follow‐up carefully. We would have appraised these critically and assessed their impact on the data in the light of the results of the review. </p> <p>We acknowledged that sometimes measures of dispersion are not recorded in trials. Where the standard error (SE) or the t‐statistic was reported, we planned to calculate standard deviations with statistical assistance from review author, PB. Where the authors did not report the aetiology of ulcers, we planned to contact them for details. Where the authors were unable to confirm aetiology, we would have excluded the study. </p> </section> <section id="CD010764-sec-0046"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD010764-sec-0047"> <h5 class="title">Clinical heterogeneity</h5> <p>We planned to determine potential reasons for heterogeneity by exploring individual study and subgroup characteristics such as age and gender of participants, risk factors for foot ulceration, duration of disease, initial size of ulcer, type of treatment, duration of follow‐up, presence or absence of infection, history of ulceration, history of significant cardiovascular events, presence or absence of PAD, type of ulcer, location of ulcer, time to ulcer healing, type of medication used, as well as how ulcer healing was defined within the context of the study. </p> </section> <section id="CD010764-sec-0048"> <h5 class="title">Methodological heterogeneity</h5> <p>We planned to use the formal assessment of bias of each study, as described above, to assist in identifying methodological heterogeneity between studies. </p> </section> <section id="CD010764-sec-0049"> <h5 class="title">Statistical heterogeneity</h5> <p>We planned to use forest plots, Q and I<sup>2</sup> statistics to assess heterogeneity (<a href="./references#CD010764-bbs2-0076" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7417):557‐60. ">Higgins 2003</a>). If heterogeneity was present, then we aimed to identify the studies that produced it, and to conduct an analysis without them. The Q‐statistic assessed for the presence of heterogeneity (<a href="./references#CD010764-bbs2-0076" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7417):557‐60. ">Higgins 2003</a>). With the I<sup>2</sup> statistic, values of 75% or more were taken as indicative of high levels of heterogeneity (<a href="./references#CD010764-bbs2-0064" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> <p>Only those studies that were clinically, methodologically and statistically homogenous were to be pooled for meta‐analysis effect‐size calculations. We planned to define subgroups for analysis using the factors we identify above as being responsible for heterogeneity. </p> </section> </section> <section id="CD010764-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>If there was a sufficient number of studies (10 or more) available, we planned to use funnel plots to assess publication bias. If there were not enough studies in the meta‐analysis for constructing a meaningful funnel plot, we would have discussed the potential for publication bias using available studies (<a href="./references#CD010764-bbs2-0109" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Sterne 2011</a>). </p> </section> <section id="CD010764-sec-0051"> <h4 class="title">Data synthesis</h4> <p>We consulted the Cochrane Collaboration recommendations and decided to conduct both random‐effects and fixed‐effect models where appropriate for any potential meta‐analysis. For example where clinical, methodological and statistical heterogeneity were not apparent, we planned to pool similar studies in a fixed‐effect model. Where any of the above‐mentioned heterogeneity was evident we would have used a random‐effects model. Where heterogeneity levels were insignificant and no other forms of heterogeneity were evident, we would have used both random‐effects and fixed‐effect models for comparison. We planned to attempt to investigate any significant differences in results and heterogeneity of studies through use of these two statistical models. If there were any vast differences between the two methods, we planned on exploring these differences. If fixed‐effect and random‐effects meta‐analyses gave identical results, then we thought that it was unlikely that there was important statistical heterogeneity, and we believed either method was appropriate for reporting. We planned to include all studies meeting the inclusion criteria and reporting outcome variables of interest in the review and we would have included all studies meeting eligibility criteria for meta‐analysis in a meta‐analysis. We planned to conduct meta‐analysis separately on provided and published data, and also on results from intention‐to‐treat trials. We would have used Review Manager (<a href="./references#CD010764-bbs2-0099" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>)for data analysis. </p> <section id="CD010764-sec-0052"> <h5 class="title">'Summary of findings' tables</h5> <p>We would have presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD010764-bbs2-0103" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach. The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD010764-bbs2-0104" title="SchünemannHJ , OxmanAD , HigginsJPT , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>). We planned to present the following outcomes in the 'Summary of findings' tables: </p> <p> <ul id="CD010764-list-0027"> <li> <p>Number of ulcers healed</p> </li> <li> <p>Time to complete ulcer healing</p> </li> <li> <p>Change in ulcer severity</p> </li> <li> <p>Incidence of amputation related to foot ulcers.</p> </li> </ul> </p> </section> </section> <section id="CD010764-sec-0053"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses at several levels in the meta‐analysis. We would have decided the subgroups after consideration of a number of factors, based on: </p> <p> <ul id="CD010764-list-0028"> <li> <p>Follow‐up time: studies stratified as short, medium and long term, where less than one year of follow‐up was to be considered as short term, one to three years as medium term, and more than three years as long term; </p> </li> <li> <p>Variation in the intervention and control group (e.g. groups who received lifestyle interventions versus anti‐diabetic medication versus insulin). </p> </li> </ul> </p> </section> <section id="CD010764-sec-0054"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out sensitivity analyses by excluding and including studies that caused heterogeneity in the data. We also planned to carry out sensitivity analyses by excluding and including studies that were deemed to be of lower quality (high risk of bias). We planned to discuss the results of the sensitivity analyses. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010764-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010764-sec-0055"></div> <section id="CD010764-sec-0056"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD010764-sec-0079" title="">Characteristics of included studies</a>,<a href="./references#CD010764-sec-0080" title="">Characteristics of excluded studies</a> and <a href="./references#CD010764-sec-0081" title="">Characteristics of ongoing studies</a>. </p> <section id="CD010764-sec-0057"> <h4 class="title">Results of the search</h4> <p>Our final database search identified 18,792 records in total. A further 726 records were identified by searching clinical trials registers, pharmaceutical trials registers and by looking through currently available clinical guidelines (see <a href="#CD010764-fig-0001">Figure 1</a>). After the removal of duplicates, the review authors screened 7994 records for inclusion based on the title and abstract matching the review inclusion criteria. This screening process further excluded 7945 articles. MF and RS reviewed 49 trials from full‐text articles or online trial registrations which were considered potentially eligible for inclusion based on the inclusion criteria. The most recent database and clinical trial registry searches were carried out in December 2015. </p> <p>We found two ongoing registered trials (<a href="./references#CD010764-bbs2-0049" title="MarfellaR . Dipeptidyl peptidase (DPP) IV inhibition facilitates healing of chronic foot ulcers in patients with type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT01472432 (accessed 10 April 2015). ">NCT01472432</a> and <a href="./references#CD010764-bbs2-0048" title="MalabuUH . Effects of Galvus (vildagliptin) on interleukin‐6 in diabetic foot ulcer. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364001 (accessed 10 April 2015). ">ACTRN12613000418774</a>) which were of potential interest (see <a href="./references#CD010764-sec-0081" title="">Characteristics of ongoing studies</a>). These are both investigating the effect of dipeptidyl peptidase‐4 (DPP‐4) inhibitors (specifically vildagliptin) on foot ulcer outcomes. No results have been published from these trials to date, however the study protocols are published in clinical trials registries. </p> <p>The first ongoing trial (<a href="./references#CD010764-bbs2-0049" title="MarfellaR . Dipeptidyl peptidase (DPP) IV inhibition facilitates healing of chronic foot ulcers in patients with type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT01472432 (accessed 10 April 2015). ">NCT01472432</a>) is investigating the clinical and humoral effects of vildagliptin on healing of chronic ulcers in people with type 2 diabetes. The experimental group in this trial will receive vildagliptin 50 mg orally twice a day for four months.The placebo group will receive oral antidiabetic therapy titrated for optimal glycaemic control for three months. The primary outcome measure is full epithelisation of the wound within four months and capillary density on punch biopsy before and after the treatments. The second ongoing trial (<a href="./references#CD010764-bbs2-0048" title="MalabuUH . Effects of Galvus (vildagliptin) on interleukin‐6 in diabetic foot ulcer. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364001 (accessed 10 April 2015). ">ACTRN12613000418774</a>) is investigating the effects of vildagliptin on inflammation markers in people with type 2 diabetes with foot ulcers. The intervention group receive oral metformin with the addition of vildagliptin for 12 weeks: the dose being determined by fasting blood glucose levels with the aim of achieving fasting glucose levels &lt; 7 mmol/l and postprandial levels of &lt; 10 mmol/l. The second group receive a similar dose of metformin and receive a placebo instead of vildagliptin. This trial has listed partial and complete wound closure within 12 weeks as a secondary outcome measure. </p> </section> <section id="CD010764-sec-0058"> <h4 class="title">Included studies</h4> <p>The only eligible study which met the inclusion criteria was a pilot trial which was undertaken to determine the feasibility of performing a definitive trial assessing the effect of close glycaemic control on healing foot ulcers in people with diabetes (<a href="./references#CD010764-bbs2-0001" title="IdrisI , GameF , JeffocoateW . Does close glycaemic control promote healing in diabetic foot ulcers? Report of a feasibility study. Diabetic Medicine2004;22:1060‐63. ">Idris 2004</a>). This pilot study was prematurely terminated due to difficulty in participant recruitment. No data was reported and so we were unable to obtain any data from this trial; see <a href="./references#CD010764-sec-0079" title="">Characteristics of included studies</a>. </p> </section> <section id="CD010764-sec-0059"> <h4 class="title">Excluded studies</h4> <p>A list of all excluded trials can be found here (see <a href="./references#CD010764-sec-0080" title="">Characteristics of excluded studies</a>). Out of the 49 trials screened for inclusion, 46 were excluded (see <a href="./references#CD010764-sec-0080" title="">Characteristics of excluded studies</a> for reasons of exclusion). Eight studies were excluded because we couldn't contact authors to obtain clarification on outcome measures, or where outcome measures were not reported (<a href="./references#CD010764-bbs2-0002" title="AbrairaC , EmanueleN , ColwellJ , HendersonW , ComstockJ , SeymorL , et al. Glycemic control and complications in Type II diabetes: design of a feasibility trial. Diabetes Care1992;15(11):1560‐71. ">Abraira 1992</a>; <a href="./references#CD010764-bbs2-0003" title="AbrairaC , DuckworthW , McCarrenM , EmanueleN , ArcaD , RedaD , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes and Its Complications2003;17:314‐22. ">Abraira 2003</a>; <a href="./references#CD010764-bbs2-0009" title="Calles‐EscandonJ , LovatoL , Simons‐MortonD , KendallD , Pop‐BusuiR , CohenR , et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33:721‐7. ">Calles‐Escandon 2010</a>; <a href="./references#CD010764-bbs2-0014" title="DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenP , et al. Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine2009;360(2):129‐39. ">Duckworth 2009</a>; <a href="./references#CD010764-bbs2-0016" title="GaedeP , VedelP , LarsenN , GunnarV , JensenG , ParvingH , et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The New England Journal Of Medicine2003;348(5):383‐93. ">Gaede 2003</a>; <a href="./references#CD010764-bbs2-0031" title="NathanD , ZinmanB , ClearyP , BlacklundJ , GenuthS , MillerR , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the Diabetes Control and Complications trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience. Archives of Internal Medicine2009;169(14):1307‐16. ">Nathan 2009</a>; <a href="./references#CD010764-bbs2-0040" title="UK Prospectice Diabetes Study (UKPDS) Group. Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837‐53. ">UK Prospective Diabetes Study (UKPDS) Group 1998</a>; <a href="./references#CD010764-bbs2-0043" title="VanOlmenJ , KuGM , VanPeltM , KalobuJ , HenH , DarrasC , et al. The effectiveness of text messages support for diabetes self‐management: protocol of the TEXT4DSM study in the democratic Republic of Congo, Cambodia and the Philippines. BMC Public Health2013;13:423‐32. ">Van Olmen 2013</a>). Another study (<a href="./references#CD010764-bbs2-0045" title="ZhangZX , LiuX , LuL , ZhangL , DiDL , LiuLH . Effect of insulin by local injection on the level of systemic blood glucose and granulation tissue formation of wound in patients with diabetic foot ulcer. Chinese Journal of Burns2011;27(6):451‐5. ">Zhang 2011</a>) investigated the effect of normal subcutaneous insulin injections in comparison to injecting half the dose of insulin at the ulcer‐site as a localised treatment and half subcutaneously, over a period of seven days. The trialists found an improvement in ulcer healing in the localised injection group with comparable fasting glucose levels, as the control group receiving the same dose of insulin. This study was published in Chinese and was translated. We excluded this study as it was not designed to compare intensive versus conventional glycaemic control on foot ulcer outcomes, especially foot ulcer healing. </p> <p>A further two trials were excluded due to non‐randomisation (<a href="./references#CD010764-bbs2-0038" title="SullivanS , Alfonso‐CristanchoR , ConnerC , HammerM , BlondeL . Long‐term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovascular Diabetology2009;8(12):1‐9. ">Sullivan 2009</a>; <a href="./references#CD010764-bbs2-0023" title="KostevK , DippelFW , RockelT , SiegmundT . Risk of diabetic foot ulceration during treatment with insulin glargine and NPH insulin. Journal of Wound Care2012;21:483‐9. ">Kostev 2012</a>) and another trial due to premature termination (<a href="./references#CD010764-bbs2-0004" title="OgrinR . Non‐weight bearing exercise in people with diabetes and foot complications. http://www.anzctr.org.au/ (accessed 10 April 2015). ">ACTRN12606000426583</a>). We contacted the trial author of <a href="./references#CD010764-bbs2-0004" title="OgrinR . Non‐weight bearing exercise in people with diabetes and foot complications. http://www.anzctr.org.au/ (accessed 10 April 2015). ">ACTRN12606000426583</a> and the authors were able to confirm that this study had been terminated before commencement. Eighteen trials were excluded due to foot ulcer outcomes not being investigated as an outcome measure (see <a href="./references#CD010764-sec-0080" title="">Characteristics of excluded studies</a>). One trial <a href="./references#CD010764-bbs2-0027" title="MarsoS , PoulterN , NissenS , NauckM , ZinmanB , DanielsG , et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. American Heart Journal2013;166:823‐30. ">Marso 2013</a> reported foot ulcers as a tertiary study outcome on their protocol, yet no data has been reported in relation to this outcome. Authors of the trial were unable to provide us with any data on foot ulcer outcomes when contacted. Therefore we also excluded this study. A further fifteen trials were excluded because participants were not exclusively placed in intensive versus conventional glycaemic control arms, as per the requirement for this review (see <a href="./references#CD010764-sec-0080" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD010764-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>We could not determine the risk of bias from the prematurely terminated included trial (<a href="./references#CD010764-bbs2-0001" title="IdrisI , GameF , JeffocoateW . Does close glycaemic control promote healing in diabetic foot ulcers? Report of a feasibility study. Diabetic Medicine2004;22:1060‐63. ">Idris 2004</a>). See <a href="#CD010764-sec-0060">Risk of bias in included studies</a>. </p> </section> <section id="CD010764-sec-0061"> <h3 class="title" id="CD010764-sec-0061">Effects of interventions</h3> <p>One eligible study was identified however this provided no data.</p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010764-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010764-sec-0062">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010764-sec-0096">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010764-sec-0062"></div> <p>This systematic review aimed to assess the effects of intensive glycaemic control compared to conventional control on the treatment of foot ulcers in people with type 1 and type 2 diabetes. We performed an exhaustive search of evidence which consisted of both published and unpublished material. Despite these efforts, we were unable to find any clinical trials which had successfully investigated the impact of intensive versus conventional glycaemic control on foot ulcer outcomes. We found one trial which was completed without any results (<a href="./references#CD010764-bbs2-0001" title="IdrisI , GameF , JeffocoateW . Does close glycaemic control promote healing in diabetic foot ulcers? Report of a feasibility study. Diabetic Medicine2004;22:1060‐63. ">Idris 2004</a>) and two ongoing trials (<a href="./references#CD010764-bbs2-0048" title="MalabuUH . Effects of Galvus (vildagliptin) on interleukin‐6 in diabetic foot ulcer. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364001 (accessed 10 April 2015). ">ACTRN12613000418774</a>; <a href="./references#CD010764-bbs2-0049" title="MarfellaR . Dipeptidyl peptidase (DPP) IV inhibition facilitates healing of chronic foot ulcers in patients with type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT01472432 (accessed 10 April 2015). ">NCT01472432</a>) which were investigating intensive versus conventional glycaemic control, and which may report foot outcomes at a later date. </p> <p>Although <a href="./references#CD010764-bbs2-0001" title="IdrisI , GameF , JeffocoateW . Does close glycaemic control promote healing in diabetic foot ulcers? Report of a feasibility study. Diabetic Medicine2004;22:1060‐63. ">Idris 2004</a> cannot contribute to current evidence due to a lack of results, there were several noteworthy points which were made by the authors. The authors of this study faced challenges in recruiting and allocating patients. A number of patients were frail or thought to be incapable of adhering to intensive glycaemic control. Recruitment is a challenge for any researcher recruiting patients to a trial of intensive diabetes control for a number of reasons.The authors reported that the attitude of people with foot ulcers towards participating in a study involving intensive glycaemic control was negative despite the potential clinical benefit. We believe factors such as the number of additional clinical consultations needed, treatment compliance and participants' ability to endure potential side effects of intensive glycaemic control may have adversely impacted on recruitment. The additional ethical clinical dilemma faced by any modern day study investigating the effects of intensive versus conventional glycaemic control is the strong precedent set by major landmark trials such as the UKPDS (<a href="./references#CD010764-bbs2-0040" title="UK Prospectice Diabetes Study (UKPDS) Group. Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837‐53. ">UK Prospective Diabetes Study (UKPDS) Group 1998</a>). These studies demonstrated a strong incentive for optimised glycaemic control. This would be especially important for a trial assessing foot ulcer healing, which is believed to be strongly influenced by hyperglycaemia. Although there remains a clear need to document the benefits associated with attempts to improve glycaemic control in this population, the perceived cost and adverse events of such a treatment needs to be taken into account in an older vulnerable population prone to the effects of hypoglycaemia. </p> <p>It is interesting to note that many of the trials investigating intensive versus conventional glycaemic control screened in this review included lower limb amputation as an outcome measure (<a href="./references#CD010764-bbs2-0005" title="AlthouseA , AbbottJ , Sutton‐TyrrellK , ForkerA , LombarderoM , BuitronL , et al. Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in Type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Cardiovascular and Metabolic Risk2013;36:3269‐75. ">Althouse 2013</a>; <a href="./references#CD010764-bbs2-0011" title="ChristensenL , AlmdalT , BoesgaardT , BreumL , DunnE , Gade‐RasmussenB , et al. Study rationale and design of the CIMT trial: The Copenhagen Insulin and Metformin Therapy trial. Diabetes, Obesity and Metabolism2009;11:315‐22. ">Christiansen 2009</a>; <a href="./references#CD010764-bbs2-0013" title="DormandyJ , CharbonnelB , EcklandD , ErdmannE , Massi‐BenefettiM , MoulesI , et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet2005;366(9493):1279‐89. ">Dormandy 2005</a>; <a href="./references#CD010764-bbs2-0016" title="GaedeP , VedelP , LarsenN , GunnarV , JensenG , ParvingH , et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The New England Journal Of Medicine2003;348(5):383‐93. ">Gaede 2003</a>; <a href="./references#CD010764-bbs2-0031" title="NathanD , ZinmanB , ClearyP , BlacklundJ , GenuthS , MillerR , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the Diabetes Control and Complications trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience. Archives of Internal Medicine2009;169(14):1307‐16. ">Nathan 2009</a>; <a href="./references#CD010764-bbs2-0036" title="PedersenO , GaedeP . Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno‐2 study. Metabolism: clinical and experimental2003;52(8):19‐23. ">Pedersen 2003</a>; <a href="./references#CD010764-bbs2-0041" title="VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaC , MaggioniA P , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism &amp; Cardiovascular Diseases2012;22:997‐1006. ">Vaccaro 2012</a>). This outcome was not, however, reported in relation to presentation with, development of, or healing of foot ulceration. Amputation was likely used rather than ulcer healing due to the ease of measurement and definitive nature of such a procedural end‐point. The clinical outcome of ulcer healing has several different definitions available in the literature and is considered more labour intensive to measure than amputation outcomes. Given that ulceration precedes lower limb amputations in up to 85% of people with diabetes who have amputations (<a href="./references#CD010764-bbs2-0055" title="BoultonAJM . The diabetic foot: from art to science: the 18th Camillo Golgi lecture. Diabetologia2004;47(8):1343‐53. ">Boulton 2004</a>; <a href="./references#CD010764-bbs2-0107" title="SinghN , ArmstrongDG , LipskyBA . Preventing foot ulcers in patients with diabetes. JAMA2005;293(2):217‐28. ">Singh 2005</a>), it would seem logical that successful ulcer healing could prevent the clinical progression towards amputation and hence be of clinical significance. None of the trials which were screened included amputation in patients who had presented with foot ulcers as a specific outcome. Amputations were reported in relation to aetiological factors, such peripheral artery disease (<a href="./references#CD010764-bbs2-0016" title="GaedeP , VedelP , LarsenN , GunnarV , JensenG , ParvingH , et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The New England Journal Of Medicine2003;348(5):383‐93. ">Gaede 2003</a>) and neuropathy (which was not well‐defined) <a href="./references#CD010764-bbs2-0031" title="NathanD , ZinmanB , ClearyP , BlacklundJ , GenuthS , MillerR , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the Diabetes Control and Complications trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience. Archives of Internal Medicine2009;169(14):1307‐16. ">Nathan 2009</a>, or the cause was entirely undefined (<a href="./references#CD010764-bbs2-0005" title="AlthouseA , AbbottJ , Sutton‐TyrrellK , ForkerA , LombarderoM , BuitronL , et al. Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in Type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Cardiovascular and Metabolic Risk2013;36:3269‐75. ">Althouse 2013</a>; <a href="./references#CD010764-bbs2-0011" title="ChristensenL , AlmdalT , BoesgaardT , BreumL , DunnE , Gade‐RasmussenB , et al. Study rationale and design of the CIMT trial: The Copenhagen Insulin and Metformin Therapy trial. Diabetes, Obesity and Metabolism2009;11:315‐22. ">Christiansen 2009</a>). One trial reported above‐the‐ankle amputations but skin lesions were not documented (<a href="./references#CD010764-bbs2-0041" title="VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaC , MaggioniA P , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism &amp; Cardiovascular Diseases2012;22:997‐1006. ">Vaccaro 2012</a>). The authors of the screened trials were unable to provide further information or data on how many amputations occurred subsequent to a foot ulcer. Therefore we were unable to include these trials. </p> <p>As foot ulceration often precedes amputation, we believe future trials should report on ulcer‐specific outcomes. It has previously been reported that the combination of patient‐specific, limb‐specific and ulcer‐specific measures should be used as outcome measures in trials focusing on diabetic foot complications and clinical care (<a href="./references#CD010764-bbs2-0084" title="JeffcoateWJ , PriceP , HardingKG , International Working Group on Wound Healing and Treatments for People with Diabetic Foot Ulcers. Wound healing and treatments for people with diabetic foot ulcers. Diabetes/Metabolism Research and Reviews2004;20(Suppl 1):S78‐89. ">Jeffcoate 2004</a>). Furthermore, the use of amputation as a stand‐alone outcome measure of ulcer healing has been questioned and needs to be carefully considered (<a href="./references#CD010764-bbs2-0090" title="MargolisDJ , JeffcoateW . Epidemiology of foot ulceration and amputation: can global variation be explained?. Medical Clinics of North America2013;97(1):791‐805. ">Margolis 2013</a>). From a patient and HRQoL point of view, foot ulcer healing may be seen as a beneficial outcome over a detrimental endpoint such as amputation. For example, in a previous meta‐analysis, intensive glycaemic control reduced the risk of amputation by 36% in people with type 2 diabetes (relative risk (RR) 0.64, 95% CI: 0.43 to 0.95; 6960 participants in eight trials) (<a href="./references#CD010764-bbs2-0075" title="HemmingsenB , LundSS , GluudC , VaagA , AlmdalT , HemmingsenC , et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008143.pub2] ">Hemmingsen 2011b</a>). Unfortunately this information was based on amputations defined in several different ways. The underlying cause of amputation varied in the trials and included a mix of ischaemic and neuropathic aetiologies. The UKPDS, which contributed almost half of the reported events in this analysis, defined amputation as major limb complications requiring lower limb amputation of a digit or any limb for any reason and included digital amputations which are usually classified as minor amputations (<a href="./references#CD010764-bbs2-0112" title="UKPDS . Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):837‐53. ">UKPDS 1998</a>). In other trials the definition of amputation has been less clear. For example it has not been clear whether minor (such as digital amputation) were grouped together with major (such as below knee) amputations (<a href="./references#CD010764-bbs2-0075" title="HemmingsenB , LundSS , GluudC , VaagA , AlmdalT , HemmingsenC , et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008143.pub2] ">Hemmingsen 2011b</a>). Overall the authors of this meta‐analysis concluded that the data provided low level evidence for a significantly reduced risk of amputation of a lower extremity using intensive glycaemic control (<a href="./references#CD010764-bbs2-0075" title="HemmingsenB , LundSS , GluudC , VaagA , AlmdalT , HemmingsenC , et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008143.pub2] ">Hemmingsen 2011b</a>). This was based on the GRADE scoring system which indicates that further research is very likely to have an important impact on the confidence in the estimate of effect and is likely to change the estimate. Other limitations in this analysis included the inability to stratify the number of reported amputations according to cause of amputation and the overall low number of reported amputations. Although this data provides evidence to support the efficacy of intensive glycaemic control in preventing amputations, its exact relationship to foot ulcer healing remains unanswered. Studies have recommended that outcomes such as ulcer‐free survival time, ulcer recurrence rate and time to ulcer healing should also be documented in clinical studies as these give important information regarding the overall effectiveness of an intervention (<a href="./references#CD010764-bbs2-0085" title="JeffcoateWJ , ChipchaseSY , InceP , GameFL . Assessing the outcome of the management of diabetic foot ulcers using ulcer‐related and person‐related measures. Diabetes Care2006;29(1):1784‐7. ">Jeffcoate 2006</a>; <a href="./references#CD010764-bbs2-0090" title="MargolisDJ , JeffcoateW . Epidemiology of foot ulceration and amputation: can global variation be explained?. Medical Clinics of North America2013;97(1):791‐805. ">Margolis 2013</a>; <a href="./references#CD010764-bbs2-0097" title="PoundN , ChipchaseS , TreeceK , GameF , JeffcoateW . Ulcer‐free survival following management of foot ulcers in diabetes. Diabetic Medicine2005;22(1):1306‐9. ">Pound 2004</a>). </p> <p>There are a plethora of factors which we believe contribute to the difficulty in performing an effective clinical trial on this particular topic and we would like to highlight a few of these which we consider to be important. There are many factors determining ulcer healing (see <a href="#CD010764-tbl-0001">Table 1</a>) which makes it challenging to investigate the impact of one variable while keeping other factors consistent. The first challenge is thus in effective randomisation with appropriate stratification of these additional risk predictors. Other determinants of ulcer healing need to be kept consistent in the intervention and control groups. Each ulcer typically involves slightly different treatments such as antibiotics, ulcer dressing and offloading, which is challenging to standardise taking into account the participants’ clinical requirements. At best a trial in a group of participants receiving multiple treatments can only provide a measure of the effect of a particular management intention.There is an added issue that some people have more than one ulcer on the same or different legs. These ulcers may respond to treatment differently. Additionally, ulcer recurrence and new ulceration are also a possibility during follow‐up. This needs to be taken into account when defining the outcome measures for such a trial. </p> <p>The presence of infection further complicates this clinical scenario and may have a profound impact on glycaemic control. Additionally, a trial investigating intensive versus conventional glycaemic control on foot ulcer outcomes needs to be able to observe an immediate effect of glycaemic control which will assist with foot ulcer healing, rather than observing long term glycaemic improvements, which is often the aim of clinical trials investigating glycaemic control. Therefore utilising mean blood glucose instead of HbA1c may be preferable in such a trial due to the ability to observe more immediate changes in glycaemic control. </p> <p>Lastly and perhaps most importantly, we believe that there is also a major sample size challenge to designing a trial in this area. Previous trials investigating the effect of intensive versus conventional glycaemic control on microvascular end points contained large sample sizes and used multiple study centres for recruitment. For example the ADVANCE trial (<a href="./references#CD010764-bbs2-0051" title="ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. ">ADVANCE 2008</a>) recruited from 215 different study centres and had 11,140 participants, and the UKPDS (<a href="./references#CD010764-bbs2-0112" title="UKPDS . Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352(9131):837‐53. ">UKPDS 1998</a>) recruited from 23 different study centres and had 5102 participants randomised to two groups. Although the difference in glycaemic control needed to demonstrate a significant statistical effect on ulcer healing is unknown, clinical guidelines recommend narrow glucose differences between intensive and conventional arms (see <a href="#CD010764-tbl-0002">Table 2</a>). This might mean that large sample sizes involving multiple centres may be required to provide adequate statistical power to observe significant differences in ulcer healing. As amputation is a binary outcome measure and as ulcer healing can be a numerical outcome measure (i.e. reduced ulcer area), it would seem plausible that sample sizes adequate for amputation outcomes should be sufficient for investigating foot ulcer healing. Appropriate sample size calculations based on multiple outcomes are however needed to understand the true extent of intensive glycaemic control on foot ulcer outcomes. Whether or not the two trials that are currently in progress (<a href="./references#CD010764-bbs2-0048" title="MalabuUH . Effects of Galvus (vildagliptin) on interleukin‐6 in diabetic foot ulcer. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364001 (accessed 10 April 2015). ">ACTRN12613000418774</a>; <a href="./references#CD010764-bbs2-0049" title="MarfellaR . Dipeptidyl peptidase (DPP) IV inhibition facilitates healing of chronic foot ulcers in patients with type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT01472432 (accessed 10 April 2015). ">NCT01472432</a>) will ultimately have enough statistical power is yet to be observed. One trial (<a href="./references#CD010764-bbs2-0048" title="MalabuUH . Effects of Galvus (vildagliptin) on interleukin‐6 in diabetic foot ulcer. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364001 (accessed 10 April 2015). ">ACTRN12613000418774</a>) has reported a proposed sample size of only 50, which suggests it is likely to be underpowered to assess the effect of the intervention on ulcer outcomes. </p> <p>The eligibility of these ongoing trials for future inclusion in this review depends on a number of factors. Most importantly this will be based on whether glycaemic levels of the intervention and control groups differ. Successful, partial or complete wound healing also needs to be observed in the trials in order to assess a relationship between glycaemic control and wound healing within the reported time‐frames of the trials. The authors of both trials have been contacted to obtain any data which may become available at a later date. </p> <p>In conducting this review, we have made exhaustive efforts to contact researchers and manufacturers of pharmaceutical agents who may have investigated foot ulcer outcomes. We do acknowledge the difficulties in identifying unpublished data and accept that some unpublished work may have been missed. It is also possible that literature published in languages other than English may have been missed. We intentionally did not exclude studies on the basis of language. We found two non‐English studies amid the full‐text trials screened for eligibility. One trial was in Chinese (<a href="./references#CD010764-bbs2-0045" title="ZhangZX , LiuX , LuL , ZhangL , DiDL , LiuLH . Effect of insulin by local injection on the level of systemic blood glucose and granulation tissue formation of wound in patients with diabetic foot ulcer. Chinese Journal of Burns2011;27(6):451‐5. ">Zhang 2011</a>) and one was in German (<a href="./references#CD010764-bbs2-0015" title="FreseniusK , FramerI . Implementation and evaluation of pharmaceutical care on the outcomes of patients suffering from diabetic foot syndrome. Krankenhauspharmazie2009;30(1):2‐10. ">Fresenius 2009</a>). These were translated into English for assessment and the original authors were contacted for any clarification. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD010764-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/media/CDSR/CD010764/urn:x-wiley:14651858:media:CD010764:CD010764-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/media/CDSR/CD010764/image_t/tCD010764-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram." data-id="CD010764-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010764.pub2/media/CDSR/CD010764/image_n/nCD010764-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/full#CD010764-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/media/CDSR/CD010764/image_n/nCD010764-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD010764-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Diabetic foot management guidelines and levels of evidence</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Guideline and management recommendations </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Level of evidence </b> </p> <p><b>(According to Oxford Centre for Evidence‐based Medicine ‐ Levels of Evidence (March 2009))</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Glycaemic target</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>National Health and Medical Research Council (NHMRC):  Prevention, identification and management of foot complications in diabetes mellitus 2011</b> </p> <p> <ul id="CD010764-list-0001"> <li> <p>Local sharp debridement</p> </li> <li> <p>Topical hydrogel dressings</p> </li> <li> <p>Pressure reduction</p> </li> <li> <p>Offloading</p> </li> <li> <p>Removable offloading</p> </li> <li> <p>Multidisciplinary care management</p> </li> <li> <p>Negative pressure therapy</p> </li> <li> <p>Hyperbaric oxygen</p> </li> <li> <p>Larval therapy</p> </li> <li> <p>Cultured skin equivalents</p> </li> <li> <p>Skin grafting</p> </li> </ul> </p> <p>Note: as per NHMRC levels of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Expert opinion</p> <p>Grade B</p> <p>Grade B</p> <p>Grade B</p> <p>Expert opinion</p> <p>Grade C</p> <p>Grade B</p> <p>Grade B</p> <p>Grade C</p> <p>Grade B</p> <p>Grade D</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>National Clearinghouse Guidelines  2011</b> </p> <p> <ul id="CD010764-list-0002"> <li> <p>Debridement with multidisciplinary team</p> </li> <li> <p>Off‐loading of foot ulcers</p> </li> <li> <p>Pressure relieving support surfaces</p> </li> <li> <p>Negative pressure wound therapy</p> </li> <li> <p>Avoid the use of:</p> <ul id="CD010764-list-0003"> <li> <p>dermal or skin substitutes</p> </li> <li> <p>electrical stimulation therapy</p> </li> <li> <p>autologous platelet‐rich plasma gel</p> </li> <li> <p>regenerative wound matrices and dalteparin</p> </li> <li> <p>growth factors</p> </li> <li> <p>hyperbaric oxygen therapy</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA1c &lt; 7%</p> <p>Level B</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>National Clearinghouse guidelines 2012</b> </p> <p><b>(treatment of neuropathic wounds)</b> </p> <p> <ul id="CD010764-list-0004"> <li> <p>Assessment by a wound expert</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>  </p> <p> </p> <p>Grade C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>National Health Service (NHS): Type 2 diabetes: prevention and management of foot problems 2004</b> </p> <p> <ul id="CD010764-list-0005"> <li> <p>Urgent attention within 24 hours</p> </li> <li> <p>Multidisciplinary treatment</p> </li> <li> <p>Multidisciplinary team comprising a podiatrist, orthotists, specialised nurse, diabetologist; with unhindered access to suites for managing major wounds, antibiotic administration, urgent inpatient facilities, community nursing, microbiology and diabetic services </p> </li> <li> <p>Prompt Revascularisation</p> </li> <li> <p>Intensive systemic antibiotic therapy</p> </li> <li> <p>Appropriate wound dressing</p> </li> <li> <p>Close monitoring and regular wound dressing changes</p> </li> <li> <p>Debridement of dead tissue</p> </li> <li> <p>Total contact casting</p> </li> <li> <p>Hyperbaric oxygen, cultured human dermis, topical ketanserin or growth factors</p> </li> <li> <p>Foot care reminders</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Grade D</p> <p>Grade D</p> <p>Grade D</p> <p>Grade D</p> <p>Grade C</p> <p>Grade D</p> <p>Grade D</p> <p>Grade B</p> <p>Grade B</p> <p>Grade D</p> <p>Grade B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Not reported</p> <p> </p> <p> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>National Health Service (NHS): 2011 National Institute for Health and Care Excellence (NICE) clinical guideline. Developed by the Centre for Clinical Practice at NICE: Diabetic foot problems: inpatient management of diabetic foot problems</b> </p> <p> <ul id="CD010764-list-0006"> <li> <p>Debridement</p> </li> <li> <p>Wound dressings</p> </li> <li> <p>Offloading</p> </li> <li> <p>Antibiotics for infection</p> </li> <li> <p>Timing for surgical management.          </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p> </p> <p> </p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p> </p> <p> </p> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2012 International Working Group on Diabetic Foot (IWGDF): Global guideline for type 2 diabetes</b> </p> <p> <ul id="CD010764-list-0007"> <li> <p>Local wound care</p> </li> <li> <p>Relief of pressure</p> </li> <li> <p>Treatment of infection</p> </li> <li> <p>Metabolic control</p> </li> <li> <p>Restoration of skin perfusion</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Not reported</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>&lt; 8 mmol/l</p> <p> </p> <p> </p> <p> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Australian diabetic foot Network: Management of diabetes related foot ulceration ‐ a clinical update</b> </p> <p> <ul id="CD010764-list-0008"> <li> <p>Debridement</p> </li> <li> <p>Dressing selection</p> </li> <li> <p>Pressure offloading</p> </li> <li> <p>Management of infection</p> </li> <li> <p>Glycaemic control</p> </li> <li> <p>Multidisciplinary care</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p> </p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p> </p> <p> Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>American College of Foot and Ankle surgeons 2006 (revision): Diabetic foot disorders – a clinical practice guideline</b> </p> <p> <ul id="CD010764-list-0009"> <li> <p>Debridement</p> </li> <li> <p>Pressure offloading</p> </li> <li> <p>Treatment of infection</p> </li> <li> <p>Optimise metabolic perturbations</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scottish Intercollegiate Guidelines Network (SIGN) Guidelines 2010</b> </p> <p> <ul id="CD010764-list-0010"> <li> <p>Referral to a multidisciplinary care team</p> </li> <li> <p>Total contact casts for unilateral ulcers</p> </li> <li> <p>Irremovable walkers</p> </li> <li> <p>Negative pressure wound therapy</p> </li> <li> <p>Arterial reconstruction for those who require it </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Grade C</p> <p>Grade B</p> <p>Grade B</p> <p>Grade B</p> <p>Grade B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>American Diabetes Association Standards of Medical Care in Diabetes 2012</b> </p> <p> <ul id="CD010764-list-0011"> <li> <p>Multidisciplinary approach</p> </li> <li> <p>Foot ulcers and wound care may require care by a podiatrist, orthopedic or vascular surgeon, or rehabilitation specialist experienced in the management of individuals with diabetes </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Grade B</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>As per position Statement for optimal Control </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Diabetic foot management guidelines and levels of evidence</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/full#CD010764-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010764-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">HbA1c targets recommended by different international guidelines ª</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Guideline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Hba1c targets in adults</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Level of Evidence</b> </p> <p><b>(According to Oxford Centre for Evidence‐based Medicine ‐ Levels of Evidence (March 2009))</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Australia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>National Health and Medical Research Council/Diabetes Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australian Paediatric Endocrine Group/ Australian Diabetes Society</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade D</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>  UK</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>National Institute for Health and Care Excellence (NICE)</p> <p> </p> <p>‐ Managing type 1 DM diabetes in adults</p> <p> </p> <p>‐ Blood glucose lowering therapy for type 2 DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>2012</p> <p>  </p> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> ≤ 7.5% if increased arterial risk</p> <p>≤ 6.5%  Between 6.5% and 7.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade B</p> <p> </p> <p>Not reported</p> <p>  </p> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scottish Intercollegiate Guidelines Network (SIGN)</p> <p> ‐ Type 1  Diabetes</p> <p> ‐ Type 2 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>No set figure</p> <p> &lt; 7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>Not reported</p> <p>Grade A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b> USA</b> </p> <p><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>National Clearinghouse</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 7% or individualize to a goal of &lt; 8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade B</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Diabetes Association</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 7% or individualise to a goal:</p> <p>&lt; 6.5%</p> <p>&lt; 8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade B</p> <p>Grade C</p> <p>Grade B</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American  Association of Clinical Endocrinologists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 6.5% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade D</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> International Diabetes Federation (IDF)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>International Diabetes Federation ‐ Global Guideline  for type 2 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 7.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U/K</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Canada</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canadian Diabetes Association</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 7%</p> <p>≤ 6.5% (may be considered to lower risk of nephropathy further)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade C, Level 3</p> <p>Grade A, Level 1A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Europe</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>European Association for the Study of Diabetes (EASD) and American Diabetes Association (ADA) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 7% or individualise to a goal of:</p> <p>6% to 6.5% (patients with short disease, duration, long life expectancy, no significant CVD) </p> <p>7.5% to8.0% (history of severe hypoglycaemia, limited life expectancy, advanced complications, extensive comorbid conditions and those in<br/> whom the target is difficult to attain) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> New Zealand</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New Zealand Group Guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade D</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ª Adapted from Australian Electronic Therapeutic Guidelines (<a href="./references#CD010764-bbs2-0067" title="ETG . Type 2 diabetes and cardiovascular disease risk. Australian Electronic Therapeutic Guidelines http://www.tg.org.au/etg_demo/phone/tgc/cvg/951.htm (accessed 10 December 2012). ">Electronic Therapeutic Guidelines Australia 2012</a>) </p> <p><b>Abbreviations</b> </p> <p>CVD = cerebrovascular disease<br/> DM = diabetes mellitus<br/> U/K = unknown </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">HbA1c targets recommended by different international guidelines ª</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/full#CD010764-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010764-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Commonly used medications in diabetes mellitus (type 1 and type 2) for the management of hyperglycaemia.</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Class/Drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Expected decrease in HbA1c</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> ORAL ANTIDIABETIC THERAPY </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfonylureas</p> <p> <ul id="CD010764-list-0012"> <li> <p>glibenclamide</p> </li> <li> <p>gliclazide</p> </li> <li> <p>glimepiride</p> </li> <li> <p>glipizide</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DPP‐4‐inhibitors</p> <p> <ul id="CD010764-list-0013"> <li> <p>sitagliptin</p> </li> <li> <p>vildagliptin,</p> </li> <li> <p>saxagliptin</p> </li> <li> <p>linagliptin</p> </li> <li> <p>anagliptin</p> </li> <li> <p>alogliptin</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% to 0.8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acarbose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% to 0.8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiazolidinedione (glitazones)</p> <p> <ul id="CD010764-list-0014"> <li> <p>pioglitazone</p> </li> <li> <p>rosglitazone</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% to 1.4%</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> PARENTERAL THERAPY</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GLP‐analogues</p> <p> <ul id="CD010764-list-0015"> <li> <p>exenatide</p> </li> <li> <p>liraglutide</p> </li> <li> <p>lixisenatide</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% to 1.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5% to 3.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Insulin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Generic name</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very‐short‐acting (rapid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aspart</p> <p>Glulisine</p> <p>Lispro</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐acting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neutral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate‐acting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Isophane (protamine suspension)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐acting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Determir</p> <p>Glargine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biphasic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neutral/isophane</p> <p>Lispro/lispro protamine</p> <p>Aspart/aspart protamine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Methods of insulin delivery</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p> <ul id="CD010764-list-0016"> <li> <p>Syringe</p> </li> <li> <p>Pen injector</p> </li> <li> <p>Pump/continuous subcutaneous insulin infusion</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Commonly used medications in diabetes mellitus (type 1 and type 2) for the management of hyperglycaemia.</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/full#CD010764-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010764-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Alternative treatments for lowering blood glucose in people with diabetic foot ulcers</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Nature of intervention</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Exercise </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Psychological and behavioural </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Dietary </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any exercise intervention that has the primary aim of improving glycaemic control in people with diabetes, where the impact of the intervention on glycaemic control and changes in an active foot ulcer has been documented </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any psychological or behavioural intervention that has the primary aim of improving glycaemic control in people with diabetes, where the impact of the intervention on glycaemic control and the resultant changes in a foot ulcer has been documented </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any dietary or nutritional intervention that has the primary aim of improving glycaemic control in people with diabetes, where the changes in glycaemic control have been correlated with changes in active foot ulcer outcome </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Examples</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exercise programmes of any intensity and duration that had the primary aim of improvement in glycaemic control </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Frequent checking of blood glucose levels, interventions aimed at good pharmaceutical practice (i.e. improving compliance with medication) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Healthy eating programmes, dietary or nutritional supplements</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Alternative treatments for lowering blood glucose in people with diabetic foot ulcers</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010764.pub2/full#CD010764-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010764.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010764-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010764-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010764-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010764-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010764-note-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD010764-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD010764-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010764-note-0011">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"/> </img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010764\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010764\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010764\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010764\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010764\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010764.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010764.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010764.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010764.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010764.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719922048"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010764.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719922052"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010764.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df4927fff937f',t:'MTc0MDcxOTkyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 